Network meta-analysis

Vomiting

Type 2 diabetes (adults)

longest follow-upRecorded harmsDoses of a drug pooledHazard ratio (from event counts)

168

Randomized trials

Treatments

91,217

Participants

6,569

Events

In plain language

Across 168 trials with 91,217 participants, 4 of 52 treatments had a clearly better result than placebo on vomiting, 21 a clearly worse one, and for 27 the evidence could not tell them apart from placebo. The most favorable estimate was for Rosiglitazone: hazard ratio (from event counts) 0.07 (95% credible interval 0.00 to 0.83).

Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Effects compared with Placebo

Hazard ratio (from event counts). Lower values favor the treatment.

Versus Placebo, log scale. Blue: Bayesian random effects posterior median with 95% credible interval (thick) and 95% prediction interval (dashed). Amber diamond: frequentist estimate with 95% confidence interval. Hover over or tab to a row for its values.

Effects of each treatment versus Placebo
Treatment	Bayesian HR (95% CrI)	95% prediction interval	Verdict
Rosiglitazone ROSIGLITAZONE	0.07 (0.00 to 0.83)	0.00 to 0.92	Better
Sulfonylurea OTHER_ACTIVE_sulfonylurea	0.08 (0.01 to 0.45)	0.01 to 0.55	Better
Insulin lispro (prandial) INS_LISPRO	0.19 (0.07 to 0.50)	0.05 to 0.66	Better
Standard care or no added treatment STANDARD_CARE	0.28 (0.03 to 1.60)	0.02 to 1.84	Unclear
Basal bolus insulin OTHER_ACTIVE_basal_bolus_insulin	0.30 (0.00 to 9.24)	0.00 to 10.62	Unclear
Insulin aspart (prandial) INS_ASPART	0.32 (0.09 to 1.04)	0.07 to 1.32	Unclear
Insulin degludec INS_DEGLUDEC	0.34 (0.11 to 1.02)	0.08 to 1.32	Unclear
Bofanglutide (GZR18) injection BOFANG_SC	0.43 (0.01 to 29.41)	0.01 to 31.44	Unclear
Premixed insulin INS_PREMIX	0.45 (0.18 to 1.00)	0.13 to 1.37	Unclear
Glimepiride GLIMEPIRIDE	0.50 (0.22 to 1.06)	0.16 to 1.50	Unclear
Canagliflozin CANAGLIFLOZIN	0.56 (0.18 to 1.62)	0.14 to 2.17	Unclear
Insulin glargine INS_GLARGINE	0.56 (0.38 to 0.81)	0.23 to 1.34	Better
Insulin icodec INS_ICODEC	0.60 (0.15 to 2.32)	0.12 to 2.93	Unclear
Pioglitazone PIOGLITAZONE	0.69 (0.30 to 1.55)	0.22 to 2.17	Unclear
Additional oad OTHER_ACTIVE_additional_OAD	0.82 (0.12 to 3.67)	0.10 to 4.60	Unclear
Sitagliptin SITAGLIPTIN	0.86 (0.55 to 1.30)	0.33 to 2.08	Unclear
Dapagliflozin DAPAGLIFLOZIN	1.01 (0.35 to 2.93)	0.27 to 3.78	Unclear
Insulin detemir INS_DETEMIR	1.02 (0.30 to 3.29)	0.24 to 4.04	Unclear
Vildagliptin VILDAGLIPTIN	1.18 (0.09 to 10.96)	0.08 to 12.56	Unclear
Exenatide extended release and dapagliflozin injection DAPAEXEN_SC	1.19 (0.35 to 3.76)	0.28 to 4.77	Unclear
Metformin METFORMIN	1.26 (0.59 to 2.62)	0.44 to 3.75	Unclear
Macupatide OTHER_ACTIVE_macupatide	1.57 (0.09 to 14.11)	0.09 to 16.16	Unclear
Insulin degludec with liraglutide injection IDEGLIRA_SC	1.61 (0.54 to 5.16)	0.42 to 6.43	Unclear
Albiglutide injection ALBI_SC	1.73 (0.89 to 3.54)	0.62 to 5.01	Unclear
Exenatide extended release injection EXENER_SC	1.93 (1.30 to 2.92)	0.77 to 4.80	Worse
Dulaglutide with macupatide injection DULAMACU_SC	1.96 (0.25 to 14.58)	0.22 to 17.17	Unclear
Retatrutide injection RETA_SC	2.13 (0.66 to 7.70)	0.51 to 9.54	Unclear
Dulaglutide injection DULA_SC	2.44 (1.81 to 3.32)	1.04 to 5.72	Worse
Insulin icodec with semaglutide injection ICOSEMA_SC	2.54 (0.91 to 7.06)	0.70 to 9.35	Unclear
Insulin glargine with lixisenatide injection IGLARLIXI_SC	2.54 (1.37 to 4.69)	0.91 to 6.87	Worse
Exenatide and rosiglitazone injection EXENROSI_SC	2.70 (0.79 to 9.57)	0.60 to 11.51	Unclear
Mazdutide injection MAZD_SC	2.75 (1.01 to 7.86)	0.77 to 10.62	Worse
Liraglutide injection LIRA_SC	2.78 (2.05 to 3.77)	1.15 to 6.64	Worse
Tirzepatide injection TIRZ_SC	2.96 (1.90 to 4.67)	1.21 to 7.41	Worse
Exenatide injection EXEN_SC	3.20 (2.29 to 4.47)	1.36 to 7.58	Worse
Semaglutide injection SEMA_SC	3.34 (2.38 to 4.71)	1.42 to 7.91	Worse
Semaglutide tablet SEMA_PO	3.44 (2.25 to 5.24)	1.43 to 8.56	Worse
Ecnoglutide injection ECNO_SC	3.71 (0.28 to 107)	0.25 to 122	Unclear
Polyethylene glycol loxenatide injection PEGLOX_SC	4.29 (0.90 to 28.74)	0.75 to 33.07	Unclear
Ecc500 po ECC500_PO	4.57 (0.34 to 151)	0.30 to 170	Unclear
Lixisenatide injection LIXI_SC	4.66 (3.43 to 6.57)	2.02 to 11.20	Worse
HRS-7535 tablet HRS7535_PO	5.21 (1.42 to 23.68)	1.14 to 28.98	Worse
Efsubaglutide alfa injection EFSUBA_SC	5.37 (1.47 to 24.29)	1.23 to 29.06	Worse
Exenimp implant EXENIMP_IMPLANT	5.93 (1.62 to 24.99)	1.31 to 30.60	Worse
Orforglipron tablet ORFO_PO	6.98 (4.26 to 11.72)	2.79 to 18.55	Worse
Cotadutide injection COTA_SC	7.77 (3.36 to 19.07)	2.43 to 25.29	Worse
Taspoglutide injection TASP_SC	7.91 (4.39 to 14.34)	2.97 to 21.51	Worse
Loti po LOTI_PO	8.30 (3.14 to 23.51)	2.32 to 30.88	Worse
Efpe sc EFPE_SC	8.98 (2.74 to 42.44)	2.16 to 52.70	Worse
Visepegenatide injection VISEPE_SC	14.88 (3.72 to 92.58)	2.90 to 112	Worse
Safiglipron (HRS-7535) tablet SAFIGL_PO	17.44 (5.30 to 66.74)	4.35 to 83.59	Worse
Danuglipron tablet DANU_PO	25.04 (4.36 to 347)	3.64 to 381	Worse

Ranking

How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.

League table

Every treatment against every other: hazard ratio (from event counts) of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.

Every treatment in a row compared with every treatment in a column
Row versus column	PLACEBO	ROSIGLITAZONE	OTHER_ACTIVE_sulfonylurea	INS_LISPRO	STANDARD_CARE	OTHER_ACTIVE_basal_bolus_insulin	INS_ASPART	INS_DEGLUDEC	BOFANG_SC	INS_PREMIX	GLIMEPIRIDE	CANAGLIFLOZIN	INS_GLARGINE	INS_ICODEC	PIOGLITAZONE	OTHER_ACTIVE_additional_OAD	SITAGLIPTIN	DAPAGLIFLOZIN	INS_DETEMIR	VILDAGLIPTIN	DAPAEXEN_SC	METFORMIN	OTHER_ACTIVE_macupatide	IDEGLIRA_SC	ALBI_SC	EXENER_SC	DULAMACU_SC	RETA_SC	DULA_SC	ICOSEMA_SC	IGLARLIXI_SC	EXENROSI_SC	MAZD_SC	LIRA_SC	TIRZ_SC	EXEN_SC	SEMA_SC	SEMA_PO	ECNO_SC	PEGLOX_SC	ECC500_PO	LIXI_SC	HRS7535_PO	EFSUBA_SC	EXENIMP_IMPLANT	ORFO_PO	COTA_SC	TASP_SC	LOTI_PO	EFPE_SC	VISEPE_SC	SAFIGL_PO	DANU_PO
PLACEBO	PLACEBO	14.09 1.20 to 497	11.95 2.24 to 111	5.16 2.00 to 14.25	3.51 0.62 to 35.06	3.32 0.11 to 224	3.14 0.96 to 11.58	2.93 0.98 to 9.39	2.34 0.03 to 184	2.25 1.00 to 5.47	2.01 0.95 to 4.46	1.78 0.62 to 5.50	1.78 1.24 to 2.61	1.65 0.43 to 6.59	1.45 0.65 to 3.37	1.23 0.27 to 8.47	1.16 0.77 to 1.83	0.99 0.34 to 2.89	0.98 0.30 to 3.31	0.85 0.09 to 11.63	0.84 0.27 to 2.87	0.79 0.38 to 1.68	0.64 0.07 to 10.75	0.62 0.19 to 1.84	0.58 0.28 to 1.13	0.52 0.34 to 0.77	0.51 0.07 to 3.94	0.47 0.13 to 1.52	0.41 0.30 to 0.55	0.39 0.14 to 1.09	0.39 0.21 to 0.73	0.37 0.10 to 1.26	0.36 0.13 to 0.99	0.36 0.27 to 0.49	0.34 0.21 to 0.53	0.31 0.22 to 0.44	0.30 0.21 to 0.42	0.29 0.19 to 0.44	0.27 0.01 to 3.51	0.23 0.03 to 1.11	0.22 0.01 to 2.95	0.21 0.15 to 0.29	0.19 0.04 to 0.70	0.19 0.04 to 0.68	0.17 0.04 to 0.62	0.14 0.09 to 0.23	0.13 0.05 to 0.30	0.13 0.07 to 0.23	0.12 0.04 to 0.32	0.11 0.02 to 0.37	0.07 0.01 to 0.27	0.06 0.01 to 0.19	0.04 0.00 to 0.23
ROSIGLITAZONE	0.07 0.00 to 0.83	ROSIGLITAZONE	0.85 0.02 to 23.40	0.37 0.01 to 5.40	0.25 0.01 to 7.59	0.22 0.00 to 32.27	0.22 0.01 to 3.70	0.20 0.01 to 3.17	0.15 0.00 to 22.08	0.16 0.00 to 2.18	0.14 0.00 to 1.89	0.13 0.00 to 1.87	0.13 0.00 to 1.54	0.11 0.00 to 1.97	0.10 0.00 to 1.36	0.09 0.00 to 1.98	0.08 0.00 to 1.01	0.07 0.00 to 1.06	0.07 0.00 to 1.12	0.06 0.00 to 2.49	0.06 0.00 to 0.94	0.06 0.00 to 0.75	0.04 0.00 to 1.88	0.04 0.00 to 0.65	0.04 0.00 to 0.52	0.04 0.00 to 0.44	0.03 0.00 to 0.90	0.03 0.00 to 0.53	0.03 0.00 to 0.34	0.03 0.00 to 0.41	0.03 0.00 to 0.35	0.03 0.00 to 0.32	0.03 0.00 to 0.38	0.03 0.00 to 0.30	0.02 0.00 to 0.29	0.02 0.00 to 0.26	0.02 0.00 to 0.25	0.02 0.00 to 0.25	0.02 0.00 to 0.71	0.02 0.00 to 0.31	0.01 0.00 to 0.68	0.02 0.00 to 0.18	0.01 0.00 to 0.24	0.01 0.00 to 0.23	0.01 0.00 to 0.20	0.01 0.00 to 0.12	0.01 0.00 to 0.12	0.01 0.00 to 0.11	0.01 0.00 to 0.12	0.01 0.00 to 0.12	0.00 0.00 to 0.09	0.00 0.00 to 0.06	0.00 0.00 to 0.06
OTHER_ACTIVE_sulfonylurea	0.08 0.01 to 0.45	1.17 0.04 to 53.62	OTHER_ACTIVE_sulfonylurea	0.43 0.04 to 3.11	0.30 0.02 to 5.23	0.27 0.00 to 26.04	0.26 0.02 to 2.10	0.25 0.02 to 1.91	0.18 0.00 to 21.31	0.19 0.02 to 1.22	0.17 0.02 to 1.06	0.15 0.01 to 1.05	0.15 0.02 to 0.82	0.14 0.01 to 1.23	0.12 0.01 to 0.77	0.10 0.01 to 1.30	0.10 0.01 to 0.54	0.08 0.01 to 0.60	0.08 0.01 to 0.62	0.07 0.00 to 1.72	0.07 0.01 to 0.55	0.07 0.01 to 0.42	0.05 0.00 to 1.28	0.05 0.00 to 0.38	0.05 0.00 to 0.29	0.04 0.00 to 0.23	0.04 0.00 to 0.60	0.04 0.00 to 0.31	0.03 0.00 to 0.19	0.03 0.00 to 0.23	0.03 0.00 to 0.19	0.03 0.00 to 0.25	0.03 0.00 to 0.21	0.03 0.00 to 0.16	0.03 0.00 to 0.16	0.03 0.00 to 0.14	0.02 0.00 to 0.13	0.02 0.00 to 0.13	0.02 0.00 to 0.50	0.02 0.00 to 0.19	0.02 0.00 to 0.43	0.02 0.00 to 0.10	0.02 0.00 to 0.13	0.01 0.00 to 0.13	0.01 0.00 to 0.12	0.01 0.00 to 0.07	0.01 0.00 to 0.07	0.01 0.00 to 0.06	0.01 0.00 to 0.07	0.01 0.00 to 0.07	0.01 0.00 to 0.05	0.00 0.00 to 0.04	0.00 0.00 to 0.04
INS_LISPRO	0.19 0.07 to 0.50	2.73 0.19 to 108	2.33 0.32 to 27.18	INS_LISPRO	0.69 0.09 to 8.06	0.63 0.02 to 45.40	0.61 0.13 to 2.98	0.56 0.14 to 2.35	0.44 0.01 to 40.36	0.44 0.12 to 1.53	0.39 0.11 to 1.30	0.35 0.08 to 1.45	0.35 0.12 to 0.92	0.32 0.06 to 1.71	0.28 0.08 to 0.97	0.24 0.04 to 1.93	0.22 0.08 to 0.64	0.19 0.04 to 0.78	0.19 0.04 to 0.87	0.16 0.01 to 2.67	0.16 0.04 to 0.74	0.15 0.04 to 0.50	0.12 0.01 to 2.35	0.12 0.03 to 0.49	0.11 0.03 to 0.34	0.10 0.03 to 0.27	0.10 0.01 to 0.92	0.09 0.02 to 0.40	0.08 0.03 to 0.21	0.08 0.02 to 0.30	0.08 0.02 to 0.23	0.07 0.01 to 0.32	0.07 0.02 to 0.29	0.07 0.02 to 0.19	0.07 0.02 to 0.16	0.06 0.02 to 0.15	0.06 0.02 to 0.16	0.06 0.02 to 0.16	0.05 0.00 to 0.80	0.04 0.01 to 0.28	0.04 0.00 to 0.70	0.04 0.01 to 0.11	0.04 0.01 to 0.19	0.04 0.01 to 0.17	0.03 0.01 to 0.15	0.03 0.01 to 0.08	0.02 0.01 to 0.09	0.02 0.01 to 0.07	0.02 0.01 to 0.09	0.02 0.00 to 0.10	0.01 0.00 to 0.07	0.01 0.00 to 0.05	0.01 0.00 to 0.06
STANDARD_CARE	0.28 0.03 to 1.60	3.99 0.13 to 194	3.36 0.19 to 53.54	1.46 0.12 to 10.95	STANDARD_CARE	0.90 0.02 to 88.23	0.89 0.07 to 7.72	0.81 0.07 to 6.58	0.61 0.00 to 73.55	0.64 0.06 to 4.35	0.57 0.05 to 3.71	0.52 0.04 to 3.82	0.50 0.05 to 2.92	0.47 0.03 to 4.26	0.41 0.04 to 2.86	0.35 0.02 to 4.41	0.33 0.03 to 1.95	0.28 0.02 to 2.07	0.28 0.02 to 2.32	0.23 0.01 to 5.64	0.24 0.02 to 1.88	0.22 0.02 to 1.47	0.18 0.01 to 4.76	0.17 0.01 to 1.35	0.16 0.02 to 1.07	0.15 0.01 to 0.85	0.14 0.01 to 1.94	0.13 0.01 to 1.04	0.12 0.01 to 0.66	0.11 0.01 to 0.81	0.11 0.01 to 0.70	0.10 0.01 to 0.81	0.10 0.01 to 0.75	0.10 0.01 to 0.55	0.10 0.01 to 0.56	0.09 0.01 to 0.50	0.09 0.01 to 0.50	0.08 0.01 to 0.47	0.07 0.00 to 1.82	0.06 0.00 to 0.73	0.06 0.00 to 1.51	0.06 0.01 to 0.34	0.05 0.00 to 0.50	0.05 0.00 to 0.44	0.05 0.00 to 0.41	0.04 0.00 to 0.24	0.04 0.00 to 0.26	0.04 0.00 to 0.22	0.03 0.00 to 0.24	0.03 0.00 to 0.27	0.02 0.00 to 0.18	0.02 0.00 to 0.13	0.01 0.00 to 0.14
OTHER_ACTIVE_basal_bolus_insulin	0.30 0.00 to 9.24	4.47 0.03 to 595	3.69 0.04 to 218	1.59 0.02 to 57.24	1.11 0.01 to 60.46	OTHER_ACTIVE_basal_bolus_insulin	0.98 0.01 to 37.20	0.88 0.01 to 33.20	0.66 0.00 to 143	0.69 0.01 to 22.99	0.61 0.01 to 20.53	0.55 0.01 to 19.18	0.54 0.01 to 16.50	0.50 0.01 to 20.13	0.45 0.01 to 14.94	0.38 0.00 to 19.06	0.36 0.01 to 10.95	0.30 0.00 to 10.56	0.30 0.00 to 11.34	0.26 0.00 to 19.45	0.25 0.00 to 9.33	0.24 0.00 to 7.76	0.21 0.00 to 14.62	0.19 0.00 to 6.80	0.17 0.00 to 5.71	0.16 0.00 to 5.03	0.15 0.00 to 8.25	0.14 0.00 to 5.33	0.12 0.00 to 3.69	0.12 0.00 to 4.22	0.12 0.00 to 3.91	0.11 0.00 to 4.26	0.11 0.00 to 3.76	0.11 0.00 to 3.37	0.10 0.00 to 3.13	0.10 0.00 to 3.01	0.09 0.00 to 2.84	0.09 0.00 to 2.70	0.07 0.00 to 6.15	0.07 0.00 to 3.18	0.06 0.00 to 5.95	0.06 0.00 to 2.02	0.06 0.00 to 2.20	0.06 0.00 to 2.16	0.05 0.00 to 1.89	0.04 0.00 to 1.32	0.04 0.00 to 1.36	0.04 0.00 to 1.26	0.04 0.00 to 1.26	0.03 0.00 to 1.29	0.02 0.00 to 0.85	0.02 0.00 to 0.67	0.01 0.00 to 0.56
INS_ASPART	0.32 0.09 to 1.04	4.55 0.27 to 185	3.79 0.48 to 48.48	1.63 0.34 to 7.92	1.13 0.13 to 14.64	1.02 0.03 to 83.01	INS_ASPART	0.93 0.17 to 4.85	0.72 0.01 to 68.15	0.72 0.15 to 3.15	0.64 0.14 to 2.66	0.56 0.11 to 2.83	0.57 0.15 to 1.91	0.53 0.08 to 3.10	0.46 0.10 to 1.99	0.39 0.05 to 3.63	0.37 0.10 to 1.31	0.32 0.06 to 1.52	0.31 0.06 to 1.69	0.27 0.02 to 4.93	0.27 0.05 to 1.49	0.25 0.06 to 0.99	0.20 0.02 to 4.36	0.20 0.04 to 0.99	0.18 0.04 to 0.72	0.17 0.04 to 0.57	0.16 0.01 to 1.66	0.15 0.02 to 0.78	0.13 0.03 to 0.43	0.12 0.02 to 0.56	0.13 0.03 to 0.48	0.12 0.02 to 0.67	0.11 0.02 to 0.56	0.11 0.03 to 0.39	0.11 0.03 to 0.38	0.10 0.03 to 0.34	0.10 0.03 to 0.29	0.09 0.02 to 0.33	0.08 0.00 to 1.47	0.07 0.01 to 0.53	0.07 0.00 to 1.24	0.07 0.02 to 0.23	0.06 0.01 to 0.38	0.06 0.01 to 0.35	0.05 0.01 to 0.31	0.05 0.01 to 0.16	0.04 0.01 to 0.18	0.04 0.01 to 0.15	0.04 0.01 to 0.17	0.03 0.00 to 0.19	0.02 0.00 to 0.14	0.02 0.00 to 0.10	0.01 0.00 to 0.11
INS_DEGLUDEC	0.34 0.11 to 1.02	4.88 0.32 to 194	4.07 0.52 to 48.96	1.78 0.43 to 7.13	1.23 0.15 to 15.10	1.14 0.03 to 84.73	1.08 0.21 to 5.72	INS_DEGLUDEC	0.78 0.01 to 70.91	0.77 0.18 to 3.07	0.69 0.17 to 2.71	0.62 0.13 to 2.83	0.61 0.19 to 1.84	0.56 0.10 to 3.25	0.49 0.12 to 1.94	0.42 0.06 to 3.87	0.40 0.12 to 1.31	0.34 0.07 to 1.60	0.34 0.07 to 1.78	0.30 0.02 to 4.92	0.29 0.06 to 1.45	0.27 0.07 to 1.01	0.22 0.02 to 4.44	0.21 0.06 to 0.70	0.20 0.05 to 0.73	0.18 0.05 to 0.56	0.17 0.02 to 1.70	0.16 0.03 to 0.78	0.14 0.04 to 0.42	0.13 0.03 to 0.60	0.14 0.04 to 0.48	0.13 0.02 to 0.67	0.12 0.03 to 0.54	0.12 0.04 to 0.38	0.12 0.04 to 0.32	0.11 0.03 to 0.33	0.10 0.03 to 0.32	0.10 0.03 to 0.33	0.09 0.00 to 1.53	0.08 0.01 to 0.55	0.07 0.00 to 1.26	0.07 0.02 to 0.22	0.06 0.01 to 0.37	0.06 0.01 to 0.34	0.06 0.01 to 0.31	0.05 0.01 to 0.16	0.04 0.01 to 0.18	0.04 0.01 to 0.15	0.04 0.01 to 0.18	0.04 0.01 to 0.20	0.02 0.00 to 0.14	0.02 0.00 to 0.10	0.01 0.00 to 0.11
BOFANG_SC	0.43 0.01 to 29.41	6.68 0.05 to 1361	5.50 0.05 to 666	2.25 0.02 to 179	1.63 0.01 to 210	1.52 0.01 to 483	1.39 0.01 to 111	1.29 0.01 to 102	BOFANG_SC	0.95 0.01 to 75.55	0.87 0.01 to 62.54	0.78 0.01 to 64.22	0.77 0.01 to 53.23	0.72 0.01 to 65.70	0.62 0.01 to 48.61	0.56 0.01 to 53.60	0.49 0.01 to 35.92	0.43 0.00 to 33.41	0.42 0.00 to 35.48	0.39 0.00 to 51.84	0.37 0.00 to 29.55	0.34 0.00 to 24.32	0.29 0.00 to 47.16	0.27 0.00 to 22.55	0.25 0.00 to 18.34	0.22 0.00 to 15.83	0.21 0.00 to 25.25	0.20 0.00 to 17.83	0.17 0.00 to 12.40	0.17 0.00 to 13.38	0.17 0.00 to 12.00	0.16 0.00 to 13.57	0.15 0.00 to 13.02	0.15 0.00 to 10.59	0.14 0.00 to 10.29	0.13 0.00 to 9.44	0.13 0.00 to 9.50	0.12 0.00 to 9.09	0.11 0.00 to 18.56	0.10 0.00 to 9.65	0.08 0.00 to 16.90	0.09 0.00 to 6.24	0.08 0.00 to 7.31	0.08 0.00 to 6.45	0.07 0.00 to 6.07	0.06 0.00 to 4.26	0.06 0.00 to 4.09	0.05 0.00 to 4.01	0.05 0.00 to 3.89	0.05 0.00 to 3.78	0.03 0.00 to 2.61	0.02 0.00 to 2.05	0.02 0.00 to 1.85
INS_PREMIX	0.45 0.18 to 1.00	6.23 0.46 to 246	5.34 0.82 to 54.58	2.27 0.65 to 8.42	1.55 0.23 to 17.18	1.45 0.04 to 108	1.40 0.32 to 6.71	1.29 0.33 to 5.60	1.05 0.01 to 89.49	INS_PREMIX	0.90 0.29 to 2.68	0.79 0.20 to 3.17	0.79 0.32 to 1.91	0.73 0.15 to 3.65	0.65 0.21 to 1.88	0.56 0.10 to 4.25	0.52 0.20 to 1.28	0.44 0.12 to 1.67	0.43 0.10 to 1.81	0.37 0.03 to 5.81	0.38 0.09 to 1.58	0.35 0.11 to 1.03	0.29 0.03 to 5.39	0.27 0.07 to 1.07	0.26 0.08 to 0.72	0.23 0.09 to 0.54	0.22 0.03 to 2.10	0.21 0.04 to 0.86	0.18 0.07 to 0.43	0.17 0.05 to 0.65	0.18 0.06 to 0.49	0.17 0.04 to 0.66	0.16 0.04 to 0.59	0.16 0.06 to 0.37	0.15 0.06 to 0.37	0.14 0.06 to 0.30	0.13 0.05 to 0.31	0.13 0.05 to 0.32	0.12 0.00 to 1.72	0.10 0.01 to 0.59	0.10 0.00 to 1.56	0.10 0.04 to 0.22	0.08 0.02 to 0.39	0.08 0.01 to 0.39	0.08 0.01 to 0.32	0.06 0.02 to 0.16	0.06 0.02 to 0.19	0.06 0.02 to 0.14	0.05 0.01 to 0.19	0.05 0.01 to 0.21	0.03 0.00 to 0.15	0.02 0.01 to 0.11	0.02 0.00 to 0.13
GLIMEPIRIDE	0.50 0.22 to 1.06	7.03 0.53 to 275	5.88 0.95 to 58.42	2.55 0.77 to 8.84	1.75 0.27 to 18.75	1.64 0.05 to 110	1.56 0.38 to 7.07	1.45 0.37 to 5.76	1.15 0.02 to 98.16	1.11 0.37 to 3.44	GLIMEPIRIDE	0.88 0.23 to 3.37	0.88 0.38 to 2.00	0.82 0.17 to 3.92	0.72 0.23 to 2.14	0.61 0.11 to 4.49	0.57 0.24 to 1.36	0.49 0.13 to 1.76	0.49 0.12 to 2.00	0.42 0.04 to 6.66	0.41 0.11 to 1.70	0.39 0.13 to 1.11	0.32 0.03 to 5.78	0.30 0.08 to 1.13	0.28 0.10 to 0.75	0.26 0.11 to 0.58	0.25 0.03 to 2.13	0.23 0.05 to 0.93	0.20 0.09 to 0.44	0.20 0.05 to 0.70	0.19 0.07 to 0.50	0.18 0.04 to 0.73	0.18 0.05 to 0.62	0.18 0.08 to 0.38	0.17 0.07 to 0.39	0.15 0.07 to 0.33	0.15 0.06 to 0.33	0.14 0.06 to 0.34	0.13 0.00 to 1.95	0.11 0.01 to 0.65	0.11 0.00 to 1.60	0.11 0.05 to 0.23	0.09 0.02 to 0.42	0.09 0.02 to 0.40	0.08 0.02 to 0.35	0.07 0.03 to 0.17	0.06 0.02 to 0.19	0.06 0.02 to 0.16	0.06 0.02 to 0.21	0.05 0.01 to 0.23	0.03 0.00 to 0.16	0.03 0.01 to 0.12	0.02 0.00 to 0.13
CANAGLIFLOZIN	0.56 0.18 to 1.62	7.96 0.53 to 329	6.68 0.95 to 77.39	2.86 0.69 to 12.49	1.93 0.26 to 24.87	1.83 0.05 to 138	1.78 0.35 to 9.22	1.62 0.35 to 7.67	1.29 0.02 to 108	1.26 0.32 to 4.95	1.13 0.30 to 4.26	CANAGLIFLOZIN	1.00 0.32 to 3.05	0.91 0.18 to 5.03	0.81 0.21 to 3.14	0.69 0.12 to 5.57	0.65 0.20 to 2.06	0.56 0.12 to 2.51	0.55 0.11 to 2.78	0.46 0.04 to 7.92	0.47 0.09 to 2.36	0.44 0.12 to 1.61	0.36 0.03 to 7.11	0.35 0.07 to 1.57	0.32 0.09 to 1.11	0.29 0.09 to 0.89	0.28 0.03 to 2.81	0.26 0.05 to 1.28	0.23 0.07 to 0.67	0.22 0.05 to 0.90	0.22 0.06 to 0.76	0.21 0.04 to 1.03	0.20 0.05 to 0.87	0.20 0.06 to 0.60	0.19 0.06 to 0.59	0.18 0.06 to 0.53	0.17 0.06 to 0.46	0.16 0.05 to 0.51	0.15 0.00 to 2.40	0.13 0.01 to 0.83	0.12 0.00 to 2.07	0.12 0.04 to 0.36	0.11 0.02 to 0.60	0.10 0.02 to 0.55	0.09 0.02 to 0.49	0.08 0.02 to 0.25	0.07 0.02 to 0.28	0.07 0.02 to 0.23	0.07 0.01 to 0.29	0.06 0.01 to 0.31	0.04 0.00 to 0.22	0.03 0.01 to 0.15	0.02 0.00 to 0.18
INS_GLARGINE	0.56 0.38 to 0.81	7.87 0.65 to 291	6.69 1.22 to 61.28	2.89 1.09 to 8.18	1.99 0.34 to 19.35	1.85 0.06 to 120	1.74 0.52 to 6.85	1.64 0.54 to 5.20	1.30 0.02 to 104	1.27 0.52 to 3.16	1.13 0.50 to 2.62	1.00 0.33 to 3.10	INS_GLARGINE	0.92 0.23 to 3.69	0.81 0.34 to 1.99	0.69 0.15 to 4.79	0.65 0.39 to 1.12	0.56 0.18 to 1.68	0.54 0.17 to 1.91	0.47 0.05 to 6.72	0.47 0.14 to 1.63	0.44 0.20 to 1.00	0.36 0.04 to 6.30	0.35 0.11 to 0.99	0.32 0.16 to 0.64	0.29 0.18 to 0.46	0.28 0.04 to 2.26	0.26 0.07 to 0.88	0.23 0.15 to 0.33	0.22 0.08 to 0.63	0.22 0.12 to 0.42	0.21 0.06 to 0.73	0.20 0.07 to 0.57	0.20 0.13 to 0.31	0.19 0.11 to 0.30	0.18 0.11 to 0.27	0.17 0.11 to 0.26	0.16 0.09 to 0.28	0.15 0.01 to 2.06	0.13 0.02 to 0.62	0.12 0.00 to 1.69	0.12 0.08 to 0.19	0.11 0.02 to 0.43	0.10 0.02 to 0.39	0.09 0.02 to 0.36	0.08 0.04 to 0.15	0.07 0.03 to 0.18	0.07 0.04 to 0.14	0.07 0.02 to 0.19	0.06 0.01 to 0.22	0.04 0.01 to 0.16	0.03 0.01 to 0.11	0.02 0.00 to 0.13
INS_ICODEC	0.60 0.15 to 2.32	8.72 0.51 to 370	7.32 0.82 to 98.02	3.12 0.58 to 16.77	2.14 0.23 to 30.53	1.98 0.05 to 162	1.87 0.32 to 11.88	1.78 0.31 to 10.52	1.39 0.02 to 139	1.36 0.27 to 6.78	1.22 0.25 to 5.91	1.09 0.20 to 5.70	1.08 0.27 to 4.41	INS_ICODEC	0.88 0.18 to 4.25	0.75 0.10 to 7.42	0.70 0.17 to 2.91	0.60 0.11 to 3.29	0.60 0.10 to 3.53	0.51 0.04 to 9.34	0.51 0.09 to 3.03	0.48 0.10 to 2.17	0.39 0.03 to 8.12	0.37 0.06 to 2.08	0.34 0.07 to 1.52	0.31 0.08 to 1.25	0.31 0.03 to 3.46	0.28 0.04 to 1.71	0.25 0.06 to 0.97	0.24 0.09 to 0.61	0.24 0.05 to 1.03	0.22 0.04 to 1.39	0.22 0.04 to 1.15	0.22 0.05 to 0.87	0.20 0.05 to 0.82	0.19 0.05 to 0.75	0.18 0.05 to 0.66	0.17 0.04 to 0.72	0.16 0.00 to 2.97	0.14 0.01 to 1.06	0.13 0.00 to 2.60	0.13 0.03 to 0.50	0.11 0.02 to 0.76	0.11 0.01 to 0.74	0.10 0.01 to 0.68	0.09 0.02 to 0.36	0.08 0.02 to 0.37	0.08 0.02 to 0.33	0.07 0.01 to 0.39	0.07 0.01 to 0.40	0.04 0.00 to 0.28	0.03 0.01 to 0.20	0.02 0.00 to 0.22
PIOGLITAZONE	0.69 0.30 to 1.55	9.89 0.74 to 364	8.26 1.30 to 87.42	3.59 1.03 to 12.56	2.44 0.35 to 28.15	2.25 0.07 to 167	2.18 0.50 to 9.97	2.03 0.52 to 8.01	1.60 0.02 to 128	1.55 0.53 to 4.72	1.40 0.47 to 4.32	1.23 0.32 to 4.78	1.24 0.50 to 2.92	1.14 0.24 to 5.45	PIOGLITAZONE	0.86 0.15 to 6.71	0.81 0.34 to 1.89	0.68 0.19 to 2.46	0.67 0.17 to 2.69	0.57 0.05 to 9.10	0.57 0.15 to 2.40	0.55 0.19 to 1.50	0.44 0.04 to 7.83	0.43 0.10 to 1.60	0.40 0.13 to 1.10	0.36 0.15 to 0.80	0.35 0.04 to 3.35	0.32 0.07 to 1.30	0.28 0.12 to 0.65	0.27 0.07 to 0.97	0.27 0.10 to 0.74	0.25 0.06 to 1.09	0.25 0.06 to 0.90	0.25 0.10 to 0.58	0.23 0.09 to 0.57	0.22 0.09 to 0.49	0.21 0.08 to 0.48	0.20 0.08 to 0.49	0.18 0.01 to 2.93	0.16 0.02 to 0.92	0.15 0.00 to 2.24	0.15 0.06 to 0.34	0.13 0.02 to 0.61	0.13 0.02 to 0.59	0.12 0.02 to 0.51	0.10 0.04 to 0.25	0.09 0.03 to 0.28	0.09 0.03 to 0.22	0.08 0.02 to 0.30	0.08 0.01 to 0.32	0.05 0.01 to 0.23	0.04 0.01 to 0.17	0.03 0.00 to 0.19
OTHER_ACTIVE_additional_OAD	0.82 0.12 to 3.67	11.31 0.51 to 551	9.63 0.77 to 149	4.15 0.52 to 26.07	2.84 0.23 to 42.19	2.62 0.05 to 214	2.56 0.28 to 18.74	2.40 0.26 to 16.20	1.79 0.02 to 187	1.80 0.24 to 10.42	1.63 0.22 to 9.02	1.44 0.18 to 8.58	1.45 0.21 to 6.81	1.34 0.13 to 9.83	1.17 0.15 to 6.63	OTHER_ACTIVE_additional_OAD	0.95 0.14 to 4.51	0.81 0.09 to 5.17	0.80 0.09 to 5.52	0.66 0.04 to 15.30	0.67 0.08 to 4.77	0.65 0.08 to 3.46	0.53 0.03 to 12.55	0.50 0.06 to 3.14	0.46 0.06 to 2.44	0.42 0.06 to 1.99	0.40 0.03 to 5.16	0.37 0.04 to 2.56	0.34 0.05 to 1.54	0.32 0.04 to 1.88	0.32 0.04 to 1.66	0.30 0.03 to 2.17	0.29 0.03 to 1.83	0.29 0.04 to 1.34	0.27 0.04 to 1.35	0.26 0.04 to 1.22	0.24 0.04 to 1.07	0.24 0.03 to 1.15	0.21 0.00 to 4.48	0.18 0.01 to 1.73	0.17 0.00 to 3.74	0.17 0.03 to 0.81	0.15 0.01 to 1.18	0.14 0.01 to 1.14	0.13 0.01 to 1.03	0.12 0.02 to 0.57	0.10 0.01 to 0.62	0.10 0.01 to 0.51	0.10 0.01 to 0.61	0.09 0.01 to 0.61	0.05 0.00 to 0.45	0.05 0.00 to 0.31	0.03 0.00 to 0.33
SITAGLIPTIN	0.86 0.55 to 1.30	12.13 0.99 to 449	10.21 1.86 to 94.40	4.45 1.56 to 12.95	3.01 0.51 to 31.05	2.80 0.09 to 198	2.68 0.76 to 10.47	2.52 0.76 to 8.50	2.02 0.03 to 158	1.93 0.78 to 4.99	1.74 0.74 to 4.14	1.54 0.48 to 4.91	1.54 0.89 to 2.55	1.43 0.34 to 5.81	1.24 0.53 to 2.94	1.05 0.22 to 7.40	SITAGLIPTIN	0.86 0.27 to 2.59	0.84 0.25 to 2.93	0.72 0.07 to 10.16	0.72 0.21 to 2.54	0.68 0.31 to 1.50	0.55 0.06 to 9.49	0.53 0.16 to 1.65	0.49 0.21 to 1.07	0.45 0.26 to 0.73	0.43 0.06 to 3.47	0.40 0.11 to 1.38	0.35 0.21 to 0.57	0.34 0.11 to 0.98	0.34 0.16 to 0.68	0.32 0.09 to 1.14	0.31 0.10 to 0.93	0.31 0.20 to 0.47	0.29 0.15 to 0.52	0.27 0.16 to 0.43	0.26 0.15 to 0.42	0.25 0.15 to 0.41	0.23 0.01 to 3.14	0.20 0.03 to 0.97	0.19 0.01 to 2.60	0.18 0.11 to 0.30	0.16 0.03 to 0.66	0.16 0.03 to 0.63	0.15 0.03 to 0.56	0.12 0.06 to 0.23	0.11 0.04 to 0.27	0.11 0.06 to 0.20	0.10 0.03 to 0.29	0.10 0.02 to 0.33	0.06 0.01 to 0.25	0.05 0.01 to 0.17	0.03 0.00 to 0.21
DAPAGLIFLOZIN	1.01 0.35 to 2.93	14.57 0.94 to 570	12.08 1.67 to 142	5.21 1.28 to 22.79	3.61 0.48 to 44.17	3.29 0.09 to 245	3.16 0.66 to 17.16	2.93 0.62 to 13.81	2.34 0.03 to 207	2.25 0.60 to 8.69	2.04 0.57 to 7.46	1.78 0.40 to 8.46	1.80 0.60 to 5.42	1.68 0.30 to 9.30	1.47 0.41 to 5.33	1.24 0.19 to 10.62	1.17 0.39 to 3.71	DAPAGLIFLOZIN	0.99 0.21 to 4.68	0.85 0.07 to 14.23	0.85 0.25 to 3.05	0.80 0.23 to 2.85	0.64 0.06 to 13.51	0.62 0.13 to 2.76	0.57 0.16 to 2.01	0.52 0.19 to 1.47	0.51 0.05 to 5.14	0.47 0.09 to 2.28	0.41 0.14 to 1.22	0.39 0.09 to 1.72	0.40 0.12 to 1.37	0.37 0.07 to 1.88	0.36 0.08 to 1.57	0.36 0.12 to 1.08	0.34 0.11 to 1.08	0.31 0.11 to 0.94	0.30 0.10 to 0.90	0.29 0.09 to 0.92	0.27 0.01 to 4.39	0.23 0.03 to 1.41	0.22 0.01 to 3.81	0.22 0.07 to 0.65	0.19 0.03 to 1.00	0.18 0.03 to 1.01	0.17 0.03 to 0.92	0.14 0.05 to 0.47	0.13 0.03 to 0.51	0.13 0.04 to 0.42	0.12 0.03 to 0.51	0.11 0.02 to 0.57	0.07 0.01 to 0.39	0.06 0.02 to 0.17	0.04 0.00 to 0.33
INS_DETEMIR	1.02 0.30 to 3.29	14.58 0.89 to 596	12.25 1.61 to 143	5.26 1.15 to 24.06	3.57 0.43 to 47.39	3.32 0.09 to 264	3.20 0.59 to 17.89	2.98 0.56 to 15.23	2.36 0.03 to 213	2.31 0.55 to 9.53	2.06 0.50 to 8.37	1.83 0.36 to 8.80	1.84 0.52 to 6.05	1.67 0.28 to 9.82	1.48 0.37 to 5.87	1.26 0.18 to 11.27	1.19 0.34 to 4.02	1.01 0.21 to 4.67	INS_DETEMIR	0.86 0.06 to 15.10	0.86 0.18 to 4.30	0.79 0.20 to 3.10	0.66 0.05 to 13.54	0.63 0.12 to 3.11	0.58 0.15 to 2.20	0.53 0.17 to 1.59	0.51 0.05 to 5.29	0.47 0.08 to 2.47	0.41 0.12 to 1.35	0.40 0.09 to 1.82	0.40 0.11 to 1.45	0.38 0.07 to 1.96	0.37 0.08 to 1.69	0.37 0.11 to 1.19	0.34 0.10 to 1.18	0.32 0.09 to 1.04	0.30 0.09 to 0.98	0.29 0.08 to 1.00	0.26 0.01 to 4.79	0.23 0.03 to 1.69	0.22 0.01 to 3.66	0.22 0.06 to 0.71	0.19 0.03 to 1.09	0.18 0.03 to 1.07	0.17 0.03 to 0.97	0.15 0.04 to 0.51	0.13 0.03 to 0.55	0.13 0.03 to 0.46	0.12 0.03 to 0.58	0.11 0.02 to 0.62	0.07 0.01 to 0.44	0.06 0.01 to 0.31	0.04 0.00 to 0.34
VILDAGLIPTIN	1.18 0.09 to 10.96	17.46 0.40 to 1156	14.52 0.58 to 342	6.10 0.37 to 69.70	4.26 0.18 to 102	3.86 0.05 to 509	3.71 0.20 to 51.19	3.39 0.20 to 42.11	2.58 0.02 to 359	2.69 0.17 to 29.90	2.40 0.15 to 26.96	2.15 0.13 to 26.16	2.12 0.15 to 20.36	1.94 0.11 to 27.75	1.74 0.11 to 18.55	1.52 0.07 to 26.50	1.39 0.10 to 13.41	1.18 0.07 to 14.25	1.16 0.07 to 15.55	VILDAGLIPTIN	0.99 0.06 to 12.81	0.94 0.06 to 9.99	0.77 0.02 to 25.86	0.71 0.04 to 8.96	0.67 0.04 to 7.28	0.61 0.04 to 5.73	0.59 0.02 to 12.55	0.55 0.03 to 7.14	0.48 0.03 to 4.47	0.46 0.03 to 5.22	0.47 0.03 to 4.67	0.43 0.02 to 5.51	0.43 0.03 to 5.10	0.43 0.03 to 3.96	0.40 0.03 to 3.87	0.37 0.03 to 3.60	0.35 0.02 to 3.34	0.35 0.02 to 3.20	0.30 0.00 to 10.19	0.26 0.01 to 4.30	0.24 0.00 to 8.07	0.25 0.02 to 2.38	0.22 0.01 to 2.96	0.21 0.01 to 2.91	0.20 0.01 to 2.66	0.17 0.01 to 1.64	0.15 0.01 to 1.60	0.15 0.01 to 1.53	0.14 0.01 to 1.69	0.13 0.01 to 1.71	0.08 0.00 to 1.18	0.07 0.00 to 0.87	0.04 0.00 to 0.88
DAPAEXEN_SC	1.19 0.35 to 3.76	17.21 1.07 to 704	14.13 1.82 to 175	6.13 1.34 to 28.24	4.17 0.53 to 54.51	3.95 0.11 to 275	3.77 0.67 to 20.93	3.48 0.69 to 18.08	2.72 0.03 to 249	2.67 0.63 to 11.11	2.43 0.59 to 9.40	2.11 0.42 to 10.92	2.14 0.61 to 6.95	1.95 0.33 to 11.38	1.75 0.42 to 6.78	1.48 0.21 to 13.15	1.39 0.39 to 4.78	1.18 0.33 to 4.03	1.16 0.23 to 5.66	1.01 0.08 to 17.28	DAPAEXEN_SC	0.93 0.24 to 3.63	0.77 0.06 to 15.94	0.73 0.14 to 3.58	0.68 0.16 to 2.56	0.62 0.19 to 1.86	0.60 0.06 to 6.40	0.55 0.09 to 2.92	0.48 0.14 to 1.58	0.47 0.10 to 2.10	0.47 0.12 to 1.73	0.44 0.08 to 2.34	0.43 0.09 to 2.06	0.43 0.12 to 1.41	0.40 0.11 to 1.35	0.37 0.11 to 1.20	0.35 0.10 to 1.17	0.35 0.09 to 1.17	0.32 0.01 to 5.33	0.27 0.03 to 1.89	0.26 0.01 to 4.74	0.26 0.07 to 0.84	0.23 0.03 to 1.34	0.22 0.03 to 1.26	0.20 0.03 to 1.12	0.17 0.04 to 0.60	0.15 0.03 to 0.65	0.15 0.04 to 0.55	0.14 0.03 to 0.65	0.13 0.02 to 0.71	0.08 0.01 to 0.50	0.07 0.01 to 0.29	0.05 0.00 to 0.40
METFORMIN	1.26 0.59 to 2.62	17.94 1.34 to 686	15.28 2.38 to 161	6.59 1.99 to 22.34	4.46 0.68 to 46.46	4.19 0.13 to 289	3.98 1.01 to 17.36	3.71 0.99 to 14.36	2.95 0.04 to 232	2.84 0.97 to 8.91	2.55 0.90 to 7.42	2.26 0.62 to 8.16	2.25 1.00 to 4.96	2.09 0.46 to 9.68	1.83 0.66 to 5.18	1.55 0.29 to 12.19	1.47 0.67 to 3.26	1.25 0.35 to 4.36	1.26 0.32 to 4.91	1.06 0.10 to 15.63	1.07 0.28 to 4.25	METFORMIN	0.81 0.08 to 14.15	0.79 0.20 to 2.94	0.72 0.26 to 1.97	0.66 0.30 to 1.37	0.64 0.07 to 5.35	0.59 0.14 to 2.37	0.52 0.25 to 1.05	0.50 0.14 to 1.72	0.50 0.19 to 1.28	0.47 0.11 to 1.94	0.46 0.13 to 1.54	0.46 0.21 to 0.97	0.43 0.18 to 0.97	0.40 0.18 to 0.86	0.38 0.17 to 0.81	0.37 0.16 to 0.84	0.34 0.01 to 4.95	0.29 0.04 to 1.41	0.28 0.01 to 4.22	0.27 0.12 to 0.59	0.24 0.05 to 1.07	0.23 0.04 to 1.05	0.22 0.04 to 0.93	0.18 0.07 to 0.43	0.16 0.05 to 0.50	0.16 0.06 to 0.39	0.15 0.04 to 0.52	0.14 0.03 to 0.58	0.08 0.01 to 0.42	0.07 0.02 to 0.29	0.05 0.00 to 0.35
OTHER_ACTIVE_macupatide	1.57 0.09 to 14.11	22.82 0.53 to 1473	18.91 0.78 to 402	8.13 0.43 to 94.95	5.65 0.21 to 120	4.86 0.07 to 550	4.89 0.23 to 63.49	4.51 0.23 to 53.54	3.45 0.02 to 446	3.50 0.19 to 37.16	3.16 0.17 to 33.47	2.82 0.14 to 34.09	2.81 0.16 to 26.21	2.58 0.12 to 32.76	2.25 0.13 to 23.05	1.88 0.08 to 36.20	1.81 0.11 to 17.53	1.56 0.07 to 17.94	1.52 0.07 to 19.28	1.30 0.04 to 40.70	1.30 0.06 to 16.32	1.23 0.07 to 12.76	OTHER_ACTIVE_macupatide	0.95 0.05 to 11.18	0.89 0.05 to 8.81	0.81 0.05 to 7.69	0.79 0.04 to 9.26	0.71 0.03 to 8.47	0.64 0.04 to 5.70	0.61 0.03 to 6.96	0.62 0.04 to 6.06	0.57 0.03 to 7.48	0.57 0.03 to 6.46	0.56 0.03 to 5.33	0.53 0.03 to 5.02	0.49 0.03 to 4.67	0.47 0.03 to 4.26	0.45 0.03 to 4.26	0.37 0.01 to 12.77	0.34 0.01 to 5.33	0.30 0.00 to 10.47	0.33 0.02 to 3.16	0.29 0.01 to 4.16	0.27 0.01 to 3.84	0.25 0.01 to 3.22	0.22 0.01 to 2.16	0.20 0.01 to 2.20	0.20 0.01 to 1.91	0.18 0.01 to 2.06	0.17 0.01 to 2.09	0.10 0.00 to 1.48	0.09 0.00 to 1.08	0.06 0.00 to 1.03
IDEGLIRA_SC	1.61 0.54 to 5.16	23.09 1.55 to 931	19.52 2.63 to 229	8.42 2.02 to 36.48	5.81 0.74 to 73.58	5.29 0.15 to 425	5.11 1.01 to 27.27	4.69 1.44 to 17.41	3.74 0.04 to 346	3.65 0.94 to 14.99	3.29 0.89 to 12.68	2.90 0.64 to 13.59	2.88 1.01 to 9.03	2.70 0.48 to 15.43	2.35 0.62 to 9.64	2.00 0.32 to 17.35	1.89 0.61 to 6.24	1.60 0.36 to 7.52	1.60 0.32 to 8.09	1.40 0.11 to 25.09	1.37 0.28 to 7.28	1.27 0.34 to 4.94	1.05 0.09 to 20.91	IDEGLIRA_SC	0.92 0.26 to 3.45	0.84 0.28 to 2.71	0.82 0.08 to 8.46	0.76 0.14 to 3.72	0.66 0.22 to 2.09	0.63 0.15 to 2.87	0.64 0.19 to 2.28	0.60 0.12 to 3.18	0.59 0.13 to 2.66	0.58 0.19 to 1.86	0.55 0.18 to 1.79	0.51 0.16 to 1.66	0.48 0.16 to 1.54	0.47 0.14 to 1.59	0.43 0.01 to 7.48	0.38 0.04 to 2.57	0.35 0.01 to 6.29	0.35 0.11 to 1.11	0.31 0.05 to 1.70	0.30 0.05 to 1.62	0.27 0.04 to 1.48	0.23 0.07 to 0.79	0.21 0.05 to 0.83	0.20 0.06 to 0.73	0.20 0.04 to 0.88	0.18 0.03 to 0.96	0.11 0.01 to 0.69	0.09 0.02 to 0.46	0.06 0.00 to 0.53
ALBI_SC	1.73 0.89 to 3.54	25.09 1.93 to 910	20.91 3.46 to 216	9.00 2.90 to 30.14	6.23 0.93 to 66.06	5.79 0.17 to 385	5.46 1.40 to 24.41	5.13 1.37 to 19.84	4.05 0.05 to 343	3.90 1.38 to 11.81	3.55 1.33 to 10.02	3.14 0.90 to 11.45	3.13 1.56 to 6.44	2.91 0.66 to 13.84	2.53 0.91 to 7.59	2.16 0.41 to 16.53	2.03 0.93 to 4.69	1.74 0.50 to 6.15	1.72 0.45 to 6.81	1.49 0.14 to 22.64	1.47 0.39 to 6.09	1.38 0.51 to 3.84	1.13 0.11 to 19.59	1.08 0.29 to 3.84	ALBI_SC	0.90 0.42 to 1.98	0.88 0.11 to 7.47	0.81 0.19 to 3.16	0.71 0.35 to 1.51	0.69 0.21 to 2.32	0.69 0.28 to 1.74	0.65 0.16 to 2.63	0.63 0.18 to 2.12	0.63 0.30 to 1.34	0.59 0.27 to 1.32	0.54 0.27 to 1.11	0.52 0.25 to 1.12	0.51 0.23 to 1.16	0.47 0.02 to 6.53	0.40 0.06 to 2.27	0.38 0.01 to 5.90	0.37 0.18 to 0.80	0.34 0.06 to 1.53	0.32 0.06 to 1.43	0.29 0.06 to 1.26	0.25 0.11 to 0.59	0.23 0.07 to 0.67	0.22 0.09 to 0.54	0.21 0.06 to 0.71	0.19 0.04 to 0.76	0.11 0.02 to 0.57	0.10 0.02 to 0.40	0.07 0.00 to 0.45
EXENER_SC	1.93 1.30 to 2.92	27.46 2.25 to 970	22.99 4.27 to 220	9.98 3.69 to 29.02	6.77 1.18 to 70.36	6.33 0.20 to 426	6.04 1.75 to 24.43	5.66 1.79 to 18.89	4.50 0.06 to 356	4.35 1.84 to 10.91	3.90 1.72 to 9.39	3.46 1.13 to 10.82	3.46 2.16 to 5.58	3.20 0.80 to 13.13	2.78 1.26 to 6.47	2.39 0.50 to 16.08	2.24 1.37 to 3.78	1.92 0.68 to 5.40	1.90 0.63 to 6.00	1.64 0.17 to 22.77	1.62 0.54 to 5.26	1.52 0.73 to 3.34	1.24 0.13 to 20.71	1.19 0.37 to 3.61	1.11 0.51 to 2.37	EXENER_SC	0.98 0.12 to 7.78	0.91 0.24 to 3.10	0.79 0.50 to 1.22	0.76 0.27 to 2.22	0.76 0.38 to 1.54	0.72 0.20 to 2.52	0.70 0.23 to 1.99	0.70 0.45 to 1.08	0.65 0.37 to 1.15	0.60 0.39 to 0.94	0.58 0.36 to 0.91	0.56 0.32 to 0.97	0.52 0.02 to 7.13	0.45 0.07 to 2.18	0.42 0.01 to 5.94	0.41 0.25 to 0.67	0.37 0.08 to 1.44	0.35 0.08 to 1.39	0.33 0.07 to 1.21	0.28 0.14 to 0.51	0.25 0.10 to 0.62	0.24 0.12 to 0.48	0.23 0.08 to 0.66	0.21 0.04 to 0.76	0.13 0.02 to 0.56	0.11 0.03 to 0.37	0.08 0.01 to 0.47
DULAMACU_SC	1.96 0.25 to 14.58	29.56 1.11 to 1487	23.82 1.67 to 455	10.31 1.08 to 93.80	7.22 0.51 to 143	6.88 0.12 to 643	6.28 0.60 to 70.37	5.81 0.59 to 58.48	4.67 0.04 to 551	4.52 0.48 to 39.38	3.96 0.47 to 33.27	3.60 0.36 to 34.28	3.55 0.44 to 27.00	3.27 0.29 to 35.13	2.86 0.30 to 24.81	2.50 0.19 to 37.36	2.31 0.29 to 18.10	1.96 0.19 to 18.72	1.95 0.19 to 20.20	1.71 0.08 to 45.92	1.67 0.16 to 16.11	1.56 0.19 to 13.83	1.27 0.11 to 24.61	1.22 0.12 to 12.33	1.14 0.13 to 9.36	1.02 0.13 to 8.11	DULAMACU_SC	0.90 0.09 to 9.93	0.80 0.10 to 6.03	0.78 0.08 to 7.29	0.78 0.10 to 6.25	0.73 0.07 to 7.52	0.71 0.08 to 6.71	0.70 0.09 to 5.31	0.67 0.08 to 5.00	0.62 0.08 to 4.75	0.59 0.07 to 4.33	0.58 0.07 to 4.43	0.52 0.01 to 14.10	0.45 0.03 to 6.07	0.42 0.01 to 11.93	0.43 0.05 to 3.19	0.38 0.03 to 4.15	0.36 0.03 to 4.21	0.33 0.03 to 3.50	0.28 0.03 to 2.18	0.26 0.03 to 2.17	0.25 0.03 to 2.00	0.24 0.02 to 2.20	0.21 0.02 to 2.17	0.13 0.01 to 1.60	0.11 0.01 to 1.13	0.08 0.00 to 1.15
RETA_SC	2.13 0.66 to 7.70	31.53 1.87 to 1310	26.42 3.22 to 324	11.18 2.47 to 57.32	7.76 0.96 to 98.62	7.22 0.19 to 573	6.73 1.28 to 42.36	6.29 1.29 to 34.44	5.08 0.06 to 465	4.85 1.16 to 22.53	4.42 1.07 to 18.61	3.86 0.78 to 21.15	3.81 1.13 to 14.14	3.59 0.59 to 22.59	3.09 0.77 to 14.21	2.69 0.39 to 23.98	2.49 0.73 to 9.43	2.11 0.44 to 11.54	2.13 0.40 to 11.78	1.82 0.14 to 33.77	1.80 0.34 to 10.69	1.69 0.42 to 7.15	1.40 0.12 to 29.64	1.32 0.27 to 7.09	1.23 0.32 to 5.18	1.10 0.32 to 4.17	1.11 0.10 to 11.33	RETA_SC	0.87 0.27 to 3.15	0.85 0.18 to 4.23	0.84 0.23 to 3.47	0.81 0.14 to 4.48	0.78 0.16 to 3.86	0.77 0.23 to 2.85	0.72 0.21 to 2.77	0.67 0.20 to 2.50	0.64 0.19 to 2.37	0.62 0.18 to 2.39	0.58 0.02 to 10.24	0.49 0.05 to 3.75	0.47 0.01 to 8.10	0.46 0.14 to 1.69	0.41 0.06 to 2.53	0.39 0.06 to 2.49	0.36 0.06 to 2.25	0.30 0.09 to 1.19	0.28 0.06 to 1.28	0.27 0.07 to 1.07	0.26 0.05 to 1.27	0.23 0.04 to 1.39	0.14 0.02 to 0.95	0.12 0.02 to 0.71	0.09 0.00 to 0.75
DULA_SC	2.44 1.81 to 3.32	34.65 2.93 to 1255	29.29 5.40 to 282	12.64 4.80 to 36.19	8.58 1.52 to 84.59	8.11 0.27 to 534	7.64 2.35 to 28.97	7.12 2.41 to 23.27	5.75 0.08 to 454	5.50 2.35 to 13.87	4.92 2.30 to 11.15	4.35 1.49 to 13.61	4.37 3.04 to 6.48	4.06 1.03 to 16.35	3.54 1.55 to 8.58	2.98 0.65 to 20.85	2.84 1.77 to 4.76	2.42 0.82 to 7.32	2.41 0.74 to 8.37	2.07 0.22 to 29.01	2.07 0.63 to 7.08	1.93 0.95 to 4.07	1.56 0.18 to 26.38	1.51 0.48 to 4.54	1.41 0.66 to 2.88	1.27 0.82 to 1.99	1.24 0.17 to 9.57	1.15 0.32 to 3.71	DULA_SC	0.97 0.34 to 2.74	0.97 0.51 to 1.84	0.90 0.25 to 3.14	0.89 0.32 to 2.41	0.88 0.60 to 1.29	0.83 0.52 to 1.33	0.76 0.51 to 1.14	0.73 0.49 to 1.09	0.71 0.43 to 1.18	0.66 0.02 to 8.96	0.57 0.09 to 2.75	0.54 0.02 to 7.47	0.52 0.34 to 0.78	0.47 0.10 to 1.77	0.45 0.10 to 1.70	0.41 0.10 to 1.56	0.35 0.20 to 0.61	0.31 0.12 to 0.78	0.31 0.16 to 0.59	0.29 0.10 to 0.82	0.27 0.06 to 0.92	0.16 0.03 to 0.69	0.14 0.04 to 0.48	0.10 0.01 to 0.58
ICOSEMA_SC	2.54 0.91 to 7.06	36.69 2.43 to 1373	30.16 4.40 to 360	13.14 3.31 to 54.43	9.01 1.23 to 112	8.36 0.24 to 608	8.02 1.78 to 41.14	7.44 1.67 to 34.61	5.98 0.07 to 518	5.75 1.53 to 21.95	5.12 1.43 to 19.03	4.53 1.12 to 19.45	4.52 1.60 to 13.13	4.19 1.64 to 11.00	3.72 1.03 to 13.47	3.13 0.53 to 26.37	2.96 1.02 to 9.00	2.55 0.58 to 10.86	2.49 0.55 to 11.55	2.17 0.19 to 34.27	2.14 0.48 to 10.11	1.99 0.58 to 7.03	1.64 0.14 to 30.55	1.59 0.35 to 6.86	1.46 0.43 to 4.77	1.32 0.45 to 3.76	1.28 0.14 to 12.45	1.18 0.24 to 5.49	1.03 0.37 to 2.92	ICOSEMA_SC	1.00 0.32 to 3.19	0.94 0.19 to 4.58	0.92 0.22 to 3.79	0.91 0.32 to 2.63	0.85 0.29 to 2.62	0.80 0.28 to 2.28	0.76 0.29 to 1.98	0.74 0.25 to 2.19	0.68 0.02 to 10.99	0.59 0.07 to 3.66	0.55 0.02 to 9.60	0.55 0.19 to 1.53	0.48 0.08 to 2.50	0.47 0.08 to 2.43	0.43 0.08 to 2.19	0.36 0.12 to 1.11	0.32 0.08 to 1.21	0.32 0.10 to 1.01	0.31 0.07 to 1.27	0.28 0.04 to 1.29	0.17 0.02 to 0.99	0.14 0.03 to 0.70	0.10 0.01 to 0.80
IGLARLIXI_SC	2.54 1.37 to 4.69	36.19 2.85 to 1314	30.30 5.29 to 290	13.09 4.34 to 41.70	8.90 1.43 to 96.12	8.39 0.26 to 578	7.92 2.09 to 33.23	7.38 2.08 to 26.98	5.86 0.08 to 474	5.69 2.04 to 16.66	5.15 2.01 to 13.74	4.54 1.32 to 16.02	4.54 2.40 to 8.63	4.20 0.97 to 19.25	3.69 1.35 to 10.34	3.15 0.60 to 22.63	2.94 1.46 to 6.30	2.51 0.73 to 8.66	2.51 0.69 to 9.50	2.11 0.21 to 31.72	2.11 0.58 to 8.52	2.00 0.78 to 5.30	1.60 0.17 to 28.55	1.56 0.44 to 5.25	1.45 0.57 to 3.57	1.32 0.65 to 2.64	1.28 0.16 to 10.47	1.19 0.29 to 4.43	1.03 0.54 to 1.97	1.00 0.31 to 3.16	IGLARLIXI_SC	0.94 0.24 to 3.58	0.92 0.28 to 2.91	0.91 0.47 to 1.77	0.85 0.41 to 1.76	0.79 0.40 to 1.54	0.76 0.38 to 1.50	0.74 0.35 to 1.55	0.67 0.02 to 9.87	0.59 0.08 to 3.07	0.54 0.02 to 8.23	0.54 0.30 to 0.95	0.48 0.10 to 2.04	0.47 0.09 to 1.93	0.43 0.10 to 1.78	0.36 0.16 to 0.80	0.32 0.11 to 0.92	0.32 0.14 to 0.74	0.31 0.09 to 0.98	0.28 0.06 to 1.04	0.17 0.03 to 0.80	0.14 0.03 to 0.56	0.10 0.01 to 0.64
EXENROSI_SC	2.70 0.79 to 9.57	38.17 3.17 to 1469	32.71 3.98 to 402	13.96 3.09 to 70.40	9.65 1.23 to 119	8.86 0.23 to 696	8.60 1.50 to 48.94	7.87 1.49 to 42.71	6.35 0.07 to 576	6.03 1.51 to 25.98	5.53 1.38 to 23.98	4.80 0.97 to 25.51	4.85 1.38 to 17.21	4.49 0.72 to 28.13	3.97 0.92 to 17.55	3.34 0.46 to 32.80	3.16 0.88 to 11.71	2.69 0.53 to 13.39	2.66 0.51 to 14.72	2.31 0.18 to 41.08	2.29 0.43 to 12.40	2.13 0.52 to 9.15	1.75 0.13 to 36.48	1.68 0.31 to 8.36	1.54 0.38 to 6.20	1.40 0.40 to 4.99	1.37 0.13 to 14.63	1.24 0.22 to 7.03	1.11 0.32 to 3.93	1.07 0.22 to 5.21	1.06 0.28 to 4.12	EXENROSI_SC	0.96 0.20 to 4.73	0.97 0.28 to 3.48	0.92 0.25 to 3.30	0.85 0.26 to 2.79	0.81 0.22 to 2.90	0.79 0.21 to 2.93	0.72 0.02 to 12.65	0.61 0.07 to 4.77	0.57 0.01 to 10.84	0.58 0.16 to 2.02	0.51 0.08 to 3.07	0.49 0.07 to 3.10	0.45 0.07 to 2.60	0.39 0.10 to 1.46	0.34 0.08 to 1.58	0.34 0.09 to 1.31	0.32 0.07 to 1.53	0.30 0.04 to 1.70	0.18 0.02 to 1.16	0.15 0.03 to 0.84	0.10 0.01 to 0.94
MAZD_SC	2.75 1.01 to 7.86	39.89 2.60 to 1558	33.06 4.71 to 375	14.38 3.51 to 59.26	9.74 1.34 to 127	9.18 0.27 to 659	8.78 1.80 to 44.36	8.05 1.85 to 38.20	6.58 0.08 to 554	6.16 1.69 to 24.56	5.59 1.61 to 20.55	5.01 1.15 to 21.36	4.93 1.76 to 14.57	4.57 0.87 to 25.72	4.03 1.11 to 15.54	3.48 0.55 to 30.39	3.21 1.08 to 9.93	2.77 0.64 to 12.09	2.73 0.59 to 13.11	2.33 0.20 to 39.53	2.33 0.49 to 11.17	2.19 0.65 to 7.85	1.77 0.15 to 34.42	1.70 0.38 to 7.52	1.58 0.47 to 5.41	1.43 0.50 to 4.31	1.40 0.15 to 12.93	1.29 0.26 to 6.30	1.13 0.42 to 3.17	1.08 0.26 to 4.61	1.08 0.34 to 3.52	1.04 0.21 to 5.06	MAZD_SC	0.99 0.35 to 2.97	0.93 0.31 to 2.86	0.86 0.30 to 2.59	0.82 0.29 to 2.39	0.80 0.27 to 2.52	0.76 0.02 to 11.71	0.64 0.07 to 4.39	0.60 0.02 to 10.48	0.59 0.21 to 1.75	0.53 0.08 to 2.82	0.51 0.09 to 2.69	0.46 0.08 to 2.41	0.39 0.13 to 1.24	0.36 0.09 to 1.39	0.35 0.11 to 1.14	0.33 0.08 to 1.41	0.30 0.05 to 1.49	0.18 0.02 to 1.06	0.16 0.03 to 0.74	0.11 0.01 to 0.92
LIRA_SC	2.78 2.05 to 3.77	39.34 3.30 to 1406	32.96 6.41 to 299	14.36 5.39 to 41.60	9.77 1.81 to 99.24	9.24 0.30 to 614	8.73 2.59 to 32.68	8.16 2.64 to 26.92	6.47 0.09 to 506	6.30 2.68 to 15.46	5.61 2.60 to 12.80	4.95 1.68 to 15.57	4.98 3.25 to 7.72	4.60 1.15 to 18.74	4.02 1.73 to 9.61	3.41 0.75 to 23.76	3.24 2.11 to 5.11	2.77 0.93 to 8.27	2.73 0.84 to 9.13	2.35 0.25 to 32.23	2.35 0.71 to 8.09	2.20 1.03 to 4.86	1.78 0.19 to 30.81	1.73 0.54 to 5.28	1.60 0.75 to 3.35	1.44 0.93 to 2.25	1.42 0.19 to 11.04	1.30 0.35 to 4.32	1.14 0.77 to 1.66	1.10 0.38 to 3.15	1.10 0.56 to 2.12	1.03 0.29 to 3.53	1.01 0.34 to 2.85	LIRA_SC	0.94 0.55 to 1.57	0.87 0.57 to 1.31	0.83 0.55 to 1.26	0.81 0.50 to 1.31	0.75 0.03 to 10.06	0.65 0.10 to 3.13	0.61 0.02 to 8.38	0.60 0.38 to 0.90	0.54 0.12 to 2.02	0.51 0.11 to 1.93	0.47 0.11 to 1.73	0.40 0.22 to 0.70	0.36 0.15 to 0.82	0.35 0.19 to 0.67	0.34 0.12 to 0.93	0.31 0.06 to 1.07	0.19 0.03 to 0.77	0.16 0.04 to 0.55	0.11 0.01 to 0.66
TIRZ_SC	2.96 1.90 to 4.67	41.48 3.40 to 1606	35.61 6.40 to 331	15.27 6.09 to 42.48	10.43 1.79 to 106	9.84 0.32 to 679	9.33 2.61 to 37.44	8.66 3.11 to 25.68	6.94 0.10 to 545	6.68 2.68 to 17.67	5.99 2.59 to 14.76	5.29 1.70 to 17.47	5.30 3.31 to 8.73	4.96 1.22 to 20.54	4.29 1.75 to 11.03	3.68 0.74 to 26.37	3.45 1.94 to 6.46	2.96 0.92 to 9.31	2.93 0.85 to 10.26	2.51 0.26 to 36.35	2.47 0.74 to 9.26	2.33 1.03 to 5.50	1.88 0.20 to 33.79	1.83 0.56 to 5.63	1.70 0.76 to 3.72	1.54 0.87 to 2.72	1.49 0.20 to 12.16	1.39 0.36 to 4.85	1.21 0.75 to 1.93	1.17 0.38 to 3.48	1.18 0.57 to 2.45	1.09 0.30 to 4.06	1.08 0.35 to 3.22	1.06 0.64 to 1.82	TIRZ_SC	0.93 0.55 to 1.56	0.89 0.52 to 1.50	0.86 0.46 to 1.61	0.80 0.03 to 10.95	0.69 0.10 to 3.52	0.64 0.02 to 9.32	0.63 0.37 to 1.08	0.57 0.12 to 2.26	0.54 0.12 to 2.16	0.50 0.11 to 1.97	0.42 0.22 to 0.84	0.38 0.14 to 1.00	0.37 0.18 to 0.77	0.35 0.11 to 1.06	0.33 0.07 to 1.19	0.20 0.03 to 0.88	0.17 0.04 to 0.59	0.12 0.01 to 0.73
EXEN_SC	3.20 2.29 to 4.47	45.07 3.86 to 1622	38.47 7.13 to 358	16.45 6.51 to 46.19	11.15 1.99 to 117	10.48 0.33 to 726	10.06 2.91 to 38.73	9.38 3.03 to 31.45	7.50 0.11 to 602	7.20 3.37 to 16.48	6.48 3.06 to 14.24	5.69 1.89 to 18.04	5.71 3.74 to 9.06	5.32 1.33 to 22.16	4.63 2.06 to 11.23	3.91 0.82 to 27.65	3.71 2.30 to 6.32	3.19 1.07 to 9.51	3.13 0.96 to 10.75	2.73 0.28 to 37.99	2.69 0.83 to 9.15	2.53 1.16 to 5.63	2.04 0.21 to 35.55	1.96 0.60 to 6.08	1.84 0.90 to 3.70	1.66 1.07 to 2.57	1.61 0.21 to 12.66	1.50 0.40 to 5.04	1.31 0.88 to 1.94	1.26 0.44 to 3.63	1.27 0.65 to 2.48	1.18 0.36 to 3.91	1.16 0.39 to 3.35	1.15 0.76 to 1.77	1.08 0.64 to 1.82	EXEN_SC	0.96 0.62 to 1.50	0.93 0.55 to 1.57	0.86 0.03 to 11.78	0.74 0.11 to 3.71	0.70 0.02 to 9.58	0.69 0.45 to 1.02	0.61 0.13 to 2.36	0.59 0.13 to 2.27	0.54 0.13 to 1.90	0.46 0.25 to 0.82	0.41 0.16 to 1.03	0.40 0.22 to 0.74	0.38 0.13 to 1.09	0.35 0.07 to 1.22	0.21 0.03 to 0.89	0.18 0.05 to 0.62	0.13 0.01 to 0.76
SEMA_SC	3.34 2.38 to 4.71	47.51 3.93 to 1711	40.04 7.48 to 371	17.30 6.41 to 49.65	11.74 2.01 to 120	10.86 0.35 to 738	10.50 3.39 to 38.18	9.80 3.13 to 32.65	7.91 0.11 to 608	7.55 3.18 to 19.28	6.74 2.99 to 16.26	5.97 2.15 to 17.59	5.98 3.91 to 9.40	5.56 1.51 to 21.40	4.86 2.08 to 11.83	4.10 0.93 to 27.74	3.88 2.41 to 6.58	3.32 1.11 to 9.92	3.28 1.02 to 11.37	2.83 0.30 to 41.34	2.83 0.86 to 9.94	2.65 1.23 to 5.94	2.13 0.23 to 36.37	2.07 0.65 to 6.25	1.93 0.89 to 4.01	1.73 1.09 to 2.75	1.69 0.23 to 13.53	1.57 0.42 to 5.25	1.37 0.92 to 2.04	1.32 0.50 to 3.42	1.32 0.67 to 2.60	1.24 0.34 to 4.47	1.22 0.42 to 3.43	1.20 0.80 to 1.82	1.13 0.67 to 1.94	1.05 0.67 to 1.62	SEMA_SC	0.98 0.58 to 1.64	0.89 0.03 to 12.13	0.78 0.11 to 3.83	0.73 0.02 to 10.41	0.72 0.45 to 1.10	0.64 0.14 to 2.44	0.62 0.14 to 2.37	0.57 0.13 to 2.13	0.48 0.26 to 0.86	0.43 0.17 to 1.06	0.42 0.22 to 0.84	0.40 0.14 to 1.15	0.37 0.08 to 1.28	0.22 0.04 to 0.95	0.19 0.05 to 0.66	0.13 0.01 to 0.79
SEMA_PO	3.44 2.25 to 5.24	48.48 3.97 to 1779	40.86 7.60 to 381	17.96 6.32 to 53.70	11.96 2.11 to 121	11.25 0.37 to 725	10.75 3.07 to 43.73	10.04 3.07 to 35.54	8.01 0.11 to 632	7.74 3.14 to 20.64	6.95 2.94 to 17.36	6.17 1.97 to 20.27	6.14 3.62 to 10.81	5.76 1.40 to 24.10	4.99 2.05 to 12.65	4.20 0.87 to 29.91	3.99 2.45 to 6.84	3.42 1.08 to 10.97	3.39 1.00 to 12.05	2.90 0.31 to 42.28	2.88 0.86 to 10.60	2.72 1.19 to 6.36	2.23 0.23 to 37.10	2.11 0.63 to 7.10	1.98 0.86 to 4.37	1.77 1.03 to 3.13	1.73 0.23 to 13.81	1.62 0.42 to 5.64	1.40 0.85 to 2.33	1.36 0.46 to 4.05	1.36 0.65 to 2.85	1.27 0.34 to 4.69	1.26 0.40 to 3.76	1.23 0.77 to 2.01	1.16 0.62 to 2.16	1.07 0.64 to 1.81	1.02 0.61 to 1.73	SEMA_PO	0.93 0.03 to 12.27	0.80 0.12 to 4.03	0.76 0.02 to 10.50	0.74 0.43 to 1.24	0.65 0.14 to 2.64	0.63 0.13 to 2.53	0.58 0.13 to 2.27	0.49 0.27 to 0.86	0.44 0.17 to 1.10	0.43 0.21 to 0.87	0.41 0.15 to 1.10	0.38 0.08 to 1.38	0.23 0.04 to 0.99	0.20 0.05 to 0.70	0.14 0.01 to 0.84
ECNO_SC	3.71 0.28 to 107	58.58 1.41 to 6206	47.74 1.99 to 2512	19.44 1.24 to 651	14.29 0.55 to 774	13.75 0.16 to 2076	11.92 0.68 to 416	11.07 0.65 to 381	8.92 0.05 to 2009	8.52 0.58 to 257	7.62 0.51 to 239	6.84 0.42 to 225	6.69 0.49 to 192	6.23 0.34 to 231	5.42 0.34 to 182	4.83 0.22 to 206	4.31 0.32 to 132	3.73 0.23 to 126	3.79 0.21 to 135	3.39 0.10 to 256	3.12 0.19 to 110	2.94 0.20 to 88.36	2.70 0.08 to 176	2.32 0.13 to 81.67	2.13 0.15 to 65.51	1.94 0.14 to 57.66	1.94 0.07 to 90.35	1.74 0.10 to 59.52	1.52 0.11 to 43.29	1.48 0.09 to 48.11	1.49 0.10 to 43.10	1.39 0.08 to 46.99	1.32 0.09 to 42.71	1.33 0.10 to 38.15	1.24 0.09 to 36.64	1.16 0.08 to 33.43	1.12 0.08 to 32.15	1.08 0.08 to 32.42	ECNO_SC	0.86 0.04 to 36.49	0.82 0.01 to 62.19	0.79 0.06 to 22.57	0.72 0.03 to 23.81	0.68 0.04 to 24.10	0.62 0.03 to 22.68	0.54 0.04 to 15.87	0.49 0.03 to 15.08	0.47 0.03 to 14.43	0.45 0.03 to 14.62	0.41 0.02 to 13.87	0.25 0.01 to 9.24	0.21 0.01 to 7.55	0.15 0.00 to 6.41
PEGLOX_SC	4.29 0.90 to 28.74	64.69 3.19 to 3170	54.67 5.27 to 995	22.98 3.55 to 188	15.91 1.38 to 311	15.00 0.31 to 1460	13.73 1.90 to 135	12.76 1.83 to 116	10.20 0.10 to 1219	9.89 1.70 to 77.71	8.80 1.54 to 68.59	7.92 1.20 to 69.54	7.65 1.60 to 53.28	7.34 0.94 to 74.78	6.28 1.08 to 49.24	5.60 0.58 to 74.91	5.02 1.03 to 34.54	4.28 0.71 to 35.74	4.35 0.59 to 39.72	3.83 0.23 to 92.53	3.74 0.53 to 35.48	3.42 0.71 to 23.38	2.92 0.19 to 83.85	2.66 0.39 to 23.73	2.48 0.44 to 17.80	2.23 0.46 to 15.00	2.23 0.16 to 35.18	2.03 0.27 to 18.39	1.76 0.36 to 11.68	1.71 0.27 to 14.40	1.71 0.33 to 12.32	1.63 0.21 to 14.95	1.57 0.23 to 13.83	1.55 0.32 to 10.30	1.45 0.28 to 10.22	1.35 0.27 to 8.93	1.29 0.26 to 8.87	1.25 0.25 to 8.58	1.17 0.03 to 28.02	PEGLOX_SC	0.95 0.02 to 25.51	0.93 0.19 to 6.41	0.83 0.10 to 8.18	0.79 0.09 to 7.87	0.74 0.09 to 7.17	0.62 0.12 to 4.24	0.56 0.09 to 4.47	0.55 0.10 to 3.98	0.52 0.08 to 4.51	0.47 0.05 to 4.57	0.29 0.03 to 3.15	0.24 0.03 to 2.26	0.17 0.01 to 2.46
ECC500_PO	4.57 0.34 to 151	73.38 1.47 to 10136	57.87 2.34 to 3373	24.41 1.43 to 886	17.79 0.66 to 949	16.79 0.17 to 3409	15.25 0.81 to 576	13.78 0.80 to 528	11.79 0.06 to 2664	10.45 0.64 to 371	9.48 0.62 to 345	8.24 0.48 to 311	8.23 0.59 to 271	7.99 0.39 to 321	6.73 0.45 to 230	6.02 0.27 to 275	5.38 0.38 to 174	4.61 0.26 to 174	4.57 0.27 to 177	4.14 0.12 to 278	3.89 0.21 to 154	3.63 0.24 to 127	3.30 0.10 to 236	2.82 0.16 to 116	2.62 0.17 to 90.88	2.36 0.17 to 77.48	2.37 0.08 to 131	2.15 0.12 to 79.87	1.86 0.13 to 62.12	1.83 0.10 to 65.32	1.84 0.12 to 61.95	1.74 0.09 to 69.31	1.67 0.10 to 63.67	1.65 0.12 to 54.03	1.56 0.11 to 53.03	1.43 0.10 to 47.39	1.38 0.10 to 45.50	1.31 0.10 to 45.05	1.22 0.02 to 91.43	1.05 0.04 to 47.63	ECC500_PO	0.99 0.07 to 32.55	0.88 0.04 to 34.89	0.84 0.04 to 35.16	0.78 0.04 to 29.65	0.66 0.05 to 21.67	0.60 0.03 to 21.15	0.58 0.04 to 19.85	0.55 0.03 to 21.49	0.50 0.02 to 20.04	0.30 0.01 to 13.33	0.26 0.01 to 10.72	0.18 0.00 to 9.29
LIXI_SC	4.66 3.43 to 6.57	66.65 5.51 to 2395	56.18 10.46 to 526	24.17 9.18 to 71.69	16.57 2.94 to 168	15.40 0.49 to 1052	14.58 4.29 to 57.08	13.75 4.45 to 46.29	10.97 0.16 to 891	10.48 4.51 to 26.55	9.42 4.32 to 22.06	8.40 2.79 to 27.08	8.36 5.40 to 13.27	7.72 1.99 to 31.65	6.75 2.90 to 16.73	5.75 1.23 to 39.96	5.41 3.32 to 9.48	4.61 1.53 to 14.41	4.56 1.41 to 16.02	3.94 0.42 to 56.27	3.89 1.19 to 14.34	3.67 1.70 to 8.43	3.01 0.32 to 49.43	2.89 0.90 to 8.92	2.68 1.25 to 5.65	2.41 1.49 to 4.02	2.35 0.31 to 18.80	2.20 0.59 to 7.30	1.91 1.28 to 2.92	1.82 0.65 to 5.38	1.84 1.05 to 3.30	1.73 0.49 to 6.08	1.69 0.57 to 4.87	1.67 1.11 to 2.63	1.58 0.93 to 2.70	1.45 0.98 to 2.24	1.39 0.91 to 2.23	1.36 0.81 to 2.33	1.26 0.04 to 16.72	1.08 0.16 to 5.39	1.01 0.03 to 14.01	LIXI_SC	0.89 0.19 to 3.42	0.86 0.19 to 3.35	0.79 0.18 to 2.95	0.67 0.37 to 1.22	0.60 0.24 to 1.48	0.59 0.31 to 1.16	0.56 0.19 to 1.64	0.52 0.11 to 1.78	0.31 0.05 to 1.33	0.27 0.07 to 0.94	0.19 0.01 to 1.11
HRS7535_PO	5.21 1.42 to 23.68	76.83 4.20 to 3134	63.98 7.78 to 932	27.51 5.17 to 170	19.11 2.00 to 288	18.02 0.45 to 1586	16.76 2.60 to 119	15.39 2.73 to 103	12.18 0.14 to 1204	11.95 2.54 to 66.20	10.73 2.36 to 58.34	9.41 1.68 to 62.70	9.43 2.34 to 45.02	8.70 1.32 to 66.54	7.68 1.65 to 41.35	6.58 0.85 to 73.22	6.09 1.52 to 30.05	5.23 1.00 to 33.49	5.22 0.92 to 34.56	4.50 0.34 to 89.17	4.42 0.75 to 30.96	4.16 0.94 to 22.11	3.42 0.24 to 78.48	3.24 0.59 to 21.07	2.98 0.65 to 15.56	2.70 0.70 to 13.03	2.65 0.24 to 34.16	2.46 0.40 to 16.82	2.14 0.56 to 9.78	2.07 0.40 to 12.44	2.08 0.49 to 10.41	1.95 0.33 to 12.93	1.89 0.35 to 12.13	1.86 0.49 to 8.65	1.76 0.44 to 8.50	1.63 0.42 to 7.61	1.56 0.41 to 7.26	1.53 0.38 to 7.33	1.40 0.04 to 29.90	1.21 0.12 to 10.53	1.14 0.03 to 23.35	1.12 0.29 to 5.21	HRS7535_PO	0.97 0.14 to 7.09	0.89 0.13 to 6.38	0.75 0.19 to 3.61	0.68 0.14 to 3.69	0.66 0.16 to 3.30	0.63 0.12 to 3.64	0.58 0.08 to 4.04	0.35 0.04 to 2.80	0.30 0.05 to 2.05	0.20 0.01 to 2.12
EFSUBA_SC	5.37 1.47 to 24.29	79.20 4.30 to 3907	68.09 7.50 to 959	28.52 5.72 to 166	19.86 2.28 to 283	18.15 0.46 to 1534	17.39 2.83 to 122	16.10 2.90 to 104	12.98 0.15 to 1201	12.32 2.60 to 67.32	11.08 2.50 to 57.64	9.76 1.81 to 60.59	9.69 2.53 to 44.86	9.01 1.36 to 67.69	7.90 1.70 to 42.68	6.93 0.87 to 73.50	6.34 1.59 to 30.83	5.44 0.99 to 33.50	5.41 0.93 to 36.76	4.70 0.34 to 96.93	4.63 0.79 to 30.91	4.30 0.95 to 23.55	3.65 0.26 to 74.93	3.38 0.62 to 20.94	3.12 0.70 to 15.41	2.83 0.72 to 12.62	2.77 0.24 to 34.51	2.57 0.40 to 16.84	2.20 0.59 to 10.02	2.14 0.41 to 13.07	2.15 0.52 to 11.01	2.03 0.32 to 13.82	1.96 0.37 to 11.58	1.95 0.52 to 8.96	1.85 0.46 to 8.63	1.68 0.44 to 7.66	1.61 0.42 to 7.33	1.59 0.40 to 7.41	1.46 0.04 to 27.90	1.27 0.13 to 10.68	1.19 0.03 to 24.75	1.16 0.30 to 5.34	1.03 0.14 to 7.37	EFSUBA_SC	0.93 0.13 to 6.52	0.79 0.19 to 3.69	0.70 0.15 to 3.89	0.69 0.16 to 3.33	0.65 0.12 to 3.83	0.59 0.08 to 4.15	0.36 0.04 to 2.90	0.31 0.05 to 1.98	0.21 0.01 to 2.05
EXENIMP_IMPLANT	5.93 1.62 to 24.99	86.94 4.97 to 3870	72.26 8.69 to 1022	30.70 6.60 to 171	21.63 2.43 to 302	20.08 0.53 to 1617	18.68 3.18 to 126	17.64 3.22 to 107	13.89 0.16 to 1274	13.33 3.08 to 67.04	12.05 2.84 to 61.52	10.71 2.03 to 61.99	10.59 2.81 to 46.92	9.86 1.48 to 71.39	8.63 1.95 to 43.51	7.53 0.97 to 73.64	6.86 1.78 to 30.94	5.92 1.08 to 33.83	5.89 1.03 to 35.56	5.09 0.38 to 98.36	5.03 0.90 to 31.64	4.65 1.07 to 23.35	3.95 0.31 to 90.29	3.66 0.68 to 22.30	3.40 0.79 to 16.06	3.06 0.83 to 13.56	3.02 0.29 to 34.51	2.79 0.45 to 16.83	2.41 0.64 to 10.27	2.35 0.46 to 12.64	2.33 0.56 to 10.42	2.20 0.38 to 14.24	2.17 0.42 to 11.98	2.12 0.58 to 9.36	1.99 0.51 to 8.97	1.84 0.53 to 7.41	1.77 0.47 to 7.69	1.71 0.44 to 7.54	1.60 0.04 to 31.47	1.35 0.14 to 10.99	1.29 0.03 to 27.05	1.27 0.34 to 5.45	1.13 0.16 to 7.90	1.08 0.15 to 7.67	EXENIMP_IMPLANT	0.84 0.21 to 3.96	0.76 0.16 to 4.15	0.75 0.18 to 3.31	0.71 0.14 to 4.05	0.65 0.09 to 4.26	0.40 0.04 to 2.87	0.33 0.05 to 2.20	0.24 0.01 to 2.34
ORFO_PO	6.98 4.26 to 11.72	98.67 8.00 to 3577	84.62 14.90 to 804	36.22 12.60 to 110	24.67 4.15 to 260	22.78 0.76 to 1643	21.84 6.27 to 88.43	20.52 6.16 to 72.72	16.49 0.23 to 1284	15.69 6.18 to 41.82	14.20 5.96 to 36.93	12.46 4.01 to 42.91	12.44 6.86 to 23.78	11.60 2.77 to 51.26	10.13 3.97 to 27.17	8.65 1.76 to 61.69	8.09 4.39 to 16.04	6.93 2.12 to 22.12	6.89 1.96 to 25.30	5.92 0.61 to 83.41	5.84 1.65 to 22.71	5.50 2.32 to 13.58	4.47 0.46 to 78.28	4.33 1.26 to 14.69	4.00 1.71 to 9.30	3.62 1.95 to 7.00	3.55 0.46 to 29.45	3.29 0.84 to 11.65	2.85 1.64 to 5.08	2.74 0.90 to 8.66	2.75 1.25 to 6.09	2.58 0.68 to 9.79	2.54 0.81 to 7.97	2.50 1.43 to 4.52	2.36 1.19 to 4.62	2.18 1.21 to 3.95	2.09 1.16 to 3.81	2.03 1.16 to 3.64	1.87 0.06 to 27.15	1.61 0.24 to 8.57	1.52 0.05 to 21.45	1.50 0.82 to 2.73	1.34 0.28 to 5.32	1.27 0.27 to 5.37	1.18 0.25 to 4.71	ORFO_PO	0.91 0.33 to 2.39	0.88 0.41 to 1.94	0.84 0.28 to 2.46	0.77 0.15 to 2.87	0.47 0.07 to 2.05	0.40 0.10 to 1.46	0.28 0.02 to 1.72
COTA_SC	7.77 3.36 to 19.07	114 8.09 to 4268	94.25 14.87 to 909	40.28 11.16 to 152	28.08 3.91 to 320	25.61 0.74 to 1825	24.62 5.61 to 122	22.75 5.54 to 95.54	18.18 0.24 to 1532	17.71 5.35 to 59.26	15.77 5.23 to 52.50	14.05 3.56 to 56.99	13.91 5.55 to 35.71	12.94 2.69 to 63.80	11.32 3.57 to 37.25	9.74 1.62 to 76.10	9.01 3.71 to 23.90	7.82 1.97 to 30.24	7.66 1.83 to 34.20	6.63 0.63 to 104	6.64 1.53 to 29.45	6.17 1.99 to 19.63	5.04 0.45 to 95.24	4.83 1.20 to 19.50	4.44 1.49 to 13.71	4.04 1.61 to 10.41	3.90 0.46 to 34.53	3.60 0.78 to 15.69	3.18 1.29 to 8.02	3.08 0.82 to 11.77	3.08 1.09 to 8.98	2.91 0.63 to 12.80	2.79 0.72 to 11.29	2.78 1.22 to 6.69	2.61 1.00 to 7.03	2.43 0.97 to 6.12	2.33 0.94 to 5.92	2.25 0.91 to 5.91	2.06 0.07 to 31.15	1.80 0.22 to 10.88	1.67 0.05 to 28.68	1.66 0.68 to 4.21	1.47 0.27 to 7.26	1.43 0.26 to 6.87	1.31 0.24 to 6.28	1.10 0.42 to 3.05	COTA_SC	0.98 0.36 to 2.80	0.93 0.24 to 3.41	0.86 0.15 to 3.80	0.53 0.07 to 2.66	0.44 0.09 to 1.89	0.31 0.02 to 2.26
TASP_SC	7.91 4.39 to 14.34	111 9.26 to 3973	94.97 16.13 to 971	41.05 13.48 to 135	27.82 4.53 to 298	25.88 0.79 to 1793	24.92 6.63 to 104	23.07 6.75 to 85.25	18.31 0.25 to 1491	17.88 7.01 to 48.33	16.12 6.37 to 42.49	14.18 4.27 to 48.40	14.14 7.31 to 27.87	13.16 3.04 to 58.06	11.44 4.47 to 30.64	9.91 1.96 to 74.11	9.20 4.98 to 18.09	7.84 2.36 to 26.36	7.81 2.16 to 29.22	6.67 0.65 to 90.64	6.65 1.82 to 25.25	6.25 2.57 to 15.86	5.11 0.52 to 95.05	4.89 1.36 to 16.61	4.51 1.87 to 11.10	4.09 2.08 to 8.14	4.02 0.50 to 33.62	3.70 0.93 to 13.85	3.23 1.69 to 6.11	3.09 0.99 to 10.19	3.13 1.35 to 7.27	2.92 0.76 to 11.16	2.88 0.87 to 9.04	2.84 1.50 to 5.38	2.68 1.29 to 5.45	2.47 1.36 to 4.46	2.37 1.20 to 4.58	2.30 1.15 to 4.66	2.14 0.07 to 30.48	1.82 0.25 to 9.66	1.71 0.05 to 26.14	1.70 0.86 to 3.20	1.51 0.30 to 6.20	1.46 0.30 to 6.07	1.33 0.30 to 5.48	1.14 0.52 to 2.43	1.02 0.36 to 2.80	TASP_SC	0.95 0.29 to 3.02	0.87 0.17 to 3.33	0.53 0.08 to 2.38	0.45 0.11 to 1.68	0.32 0.02 to 2.04
LOTI_PO	8.30 3.14 to 23.51	119 8.56 to 4789	101 13.91 to 1156	43.22 11.04 to 182	29.83 4.09 to 353	27.51 0.80 to 1907	26.51 5.76 to 137	24.50 5.57 to 115	19.46 0.26 to 1693	18.86 5.14 to 69.82	16.97 4.80 to 61.19	15.05 3.47 to 67.39	14.94 5.20 to 44.37	13.91 2.58 to 76.20	12.10 3.28 to 45.51	10.47 1.64 to 89.07	9.74 3.47 to 29.10	8.34 1.98 to 35.53	8.29 1.73 to 39.88	7.01 0.59 to 118	7.10 1.53 to 34.90	6.62 1.91 to 23.26	5.48 0.49 to 106	5.13 1.13 to 23.59	4.81 1.42 to 16.62	4.32 1.51 to 12.96	4.16 0.45 to 42.68	3.86 0.78 to 18.85	3.41 1.22 to 9.78	3.22 0.79 to 13.95	3.28 1.02 to 10.82	3.08 0.66 to 14.49	3.04 0.71 to 12.30	2.98 1.08 to 8.48	2.82 0.95 to 8.86	2.60 0.92 to 7.62	2.48 0.87 to 7.34	2.43 0.91 to 6.71	2.22 0.07 to 36.14	1.92 0.22 to 12.88	1.81 0.05 to 31.64	1.79 0.61 to 5.26	1.60 0.27 to 8.31	1.53 0.26 to 8.04	1.40 0.25 to 7.26	1.18 0.41 to 3.63	1.07 0.29 to 4.13	1.05 0.33 to 3.47	LOTI_PO	0.92 0.15 to 4.46	0.55 0.07 to 3.16	0.47 0.09 to 2.33	0.33 0.02 to 2.64
EFPE_SC	8.98 2.74 to 42.44	136 8.18 to 5939	113 13.75 to 1646	47.12 10.06 to 295	33.45 3.68 to 494	30.90 0.78 to 2575	28.95 5.20 to 212	27.04 5.11 to 170	21.97 0.26 to 2133	20.47 4.83 to 120	18.43 4.39 to 102	16.46 3.21 to 108	16.11 4.58 to 77.54	15.16 2.47 to 112	13.16 3.10 to 78.62	11.66 1.63 to 119	10.51 2.99 to 52.37	9.11 1.75 to 58.10	9.20 1.63 to 60.24	7.85 0.59 to 169	7.71 1.41 to 55.02	7.23 1.73 to 38.51	6.01 0.48 to 130	5.67 1.04 to 37.07	5.23 1.31 to 27.58	4.68 1.31 to 22.68	4.71 0.46 to 56.67	4.26 0.72 to 27.58	3.69 1.08 to 17.17	3.54 0.77 to 22.66	3.54 0.96 to 17.82	3.38 0.59 to 22.97	3.30 0.67 to 20.46	3.22 0.94 to 15.74	3.04 0.84 to 14.53	2.82 0.82 to 13.68	2.70 0.78 to 13.07	2.62 0.73 to 12.97	2.45 0.07 to 50.25	2.13 0.22 to 18.95	1.99 0.05 to 40.90	1.92 0.56 to 9.19	1.74 0.25 to 12.39	1.69 0.24 to 12.20	1.54 0.23 to 11.39	1.30 0.35 to 6.54	1.17 0.26 to 6.65	1.15 0.30 to 5.85	1.08 0.22 to 6.57	EFPE_SC	0.61 0.06 to 4.76	0.52 0.08 to 3.56	0.36 0.02 to 4.02
VISEPE_SC	14.88 3.72 to 92.58	232 11.60 to 10213	188 19.81 to 3123	78.57 13.92 to 601	54.81 5.53 to 949	53.01 1.18 to 4317	48.27 7.18 to 423	44.33 7.29 to 368	35.57 0.38 to 3999	33.48 6.79 to 252	30.72 6.24 to 224	27.24 4.55 to 233	27.05 6.21 to 167	25.14 3.54 to 245	21.68 4.30 to 163	19.18 2.22 to 252	17.48 4.07 to 114	15.03 2.55 to 120	15.09 2.28 to 128	13.11 0.84 to 327	12.76 1.99 to 110	11.81 2.38 to 82.23	10.17 0.68 to 272	9.34 1.46 to 76.58	8.71 1.74 to 58.43	7.70 1.80 to 50.27	7.91 0.63 to 116	7.09 1.05 to 58.05	6.11 1.46 to 38.33	5.93 1.01 to 48.39	5.96 1.25 to 39.77	5.59 0.86 to 46.23	5.43 0.94 to 43.11	5.38 1.29 to 34.06	5.05 1.14 to 32.49	4.66 1.12 to 29.27	4.48 1.05 to 28.33	4.34 1.02 to 27.55	3.99 0.11 to 97.73	3.48 0.32 to 39.01	3.33 0.07 to 81.20	3.19 0.75 to 19.35	2.85 0.36 to 27.27	2.79 0.34 to 24.84	2.53 0.35 to 24.18	2.14 0.49 to 13.83	1.90 0.38 to 14.87	1.90 0.42 to 12.67	1.82 0.32 to 13.65	1.63 0.21 to 15.50	VISEPE_SC	0.86 0.12 to 7.47	0.60 0.03 to 7.60
SAFIGL_PO	17.44 5.30 to 66.74	259 15.67 to 10833	217 26.40 to 2724	92.35 18.88 to 499	63.27 7.62 to 833	58.73 1.49 to 4792	56.23 10.06 to 362	51.52 10.30 to 300	42.52 0.49 to 4009	40.17 9.37 to 198	35.83 8.60 to 167	31.49 6.55 to 184	31.36 9.11 to 125	29.73 4.90 to 197	25.45 6.05 to 125	22.11 3.27 to 214	20.34 5.86 to 84.21	17.55 6.01 to 58.35	17.62 3.17 to 105	15.18 1.15 to 301	15.02 3.45 to 74.44	13.96 3.47 to 64.10	11.65 0.93 to 253	11.01 2.15 to 61.03	10.12 2.52 to 45.04	9.07 2.72 to 34.92	9.01 0.89 to 102	8.24 1.41 to 50.20	7.14 2.09 to 27.75	6.97 1.44 to 37.83	6.98 1.79 to 30.15	6.52 1.19 to 39.59	6.34 1.35 to 33.32	6.29 1.83 to 24.43	5.88 1.68 to 23.90	5.47 1.61 to 21.71	5.22 1.52 to 20.79	5.10 1.42 to 20.83	4.79 0.13 to 90.62	4.10 0.44 to 30.64	3.90 0.09 to 73.19	3.74 1.06 to 14.73	3.36 0.49 to 20.92	3.23 0.50 to 21.17	3.00 0.45 to 19.27	2.52 0.68 to 10.39	2.27 0.53 to 11.14	2.21 0.59 to 9.52	2.12 0.43 to 11.18	1.93 0.28 to 12.05	1.17 0.13 to 8.31	SAFIGL_PO	0.70 0.04 to 6.49
DANU_PO	25.04 4.36 to 347	401 15.79 to 25517	322 24.13 to 9087	131 17.47 to 2030	96.70 7.24 to 2534	88.22 1.77 to 11537	80.81 9.25 to 1418	74.52 8.97 to 1297	60.83 0.54 to 8755	56.45 7.97 to 866	51.22 7.55 to 724	46.11 5.54 to 763	44.86 7.43 to 610	42.05 4.54 to 779	36.76 5.16 to 562	33.24 3.05 to 703	29.50 4.73 to 426	25.42 3.05 to 394	25.38 2.90 to 424	22.24 1.14 to 871	21.71 2.51 to 347	19.99 2.88 to 295	17.30 0.97 to 747	15.64 1.90 to 278	14.38 2.21 to 213	13.07 2.13 to 184	13.22 0.87 to 348	11.67 1.34 to 202	10.19 1.72 to 148	9.82 1.25 to 166	9.89 1.55 to 144	9.57 1.06 to 154	9.26 1.09 to 148	9.04 1.52 to 124	8.43 1.37 to 125	7.76 1.31 to 108	7.51 1.26 to 106	7.37 1.19 to 107	6.79 0.16 to 270	5.95 0.41 to 117	5.52 0.11 to 227	5.38 0.90 to 75.30	4.90 0.47 to 89.71	4.67 0.49 to 81.51	4.25 0.43 to 75.85	3.59 0.58 to 52.37	3.21 0.44 to 50.53	3.13 0.49 to 45.31	3.04 0.38 to 48.50	2.76 0.25 to 49.81	1.66 0.13 to 31.90	1.44 0.15 to 25.55	DANU_PO

Heterogeneity, fit and convergence

Bayesian random effects (primary)

Heterogeneity (tau): 0.395 (95% CrI 0.252 to 0.552), log scale
Residual deviance: 379.1 for 360 data points
DIC: 623.4 (pD 244.3)
Largest R-hat: 1.006
Smallest ESS: bulk 1,009, tail 2,516
Divergent transitions: 0
Convergence: All criteria met
Priors: PR02 N(0, 5^2); PR05 N(0, 2.5^2); PR09 log normal(-2.1, 1.58^2) on tau^2 (Adverse events, pharm vs pharm)

Inconsistency

Do trials comparing two treatments directly agree with the indirect evidence through other treatments?

No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting.

Small study effects

A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.

Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.

Baseline effect modifiers and prognostic factors per trial
Trial	Sex (percent female) effect modifier, prognostic factor; 164 of 168
NCT03131687 S000010	46.85
NCT00754988 S000027	44.91
NCT05407961 S000034	23.57 100 minus male share
NCT00518115 S000060	51.52
NCT01296412 S000080	45 100 minus male share
NCT00838916 S000099	43.94
SURPASS-6 S000108	57.68
PIONEER 4 S000133	48
NCT04965506 S000140	40.79
MAGNA VICTORIA S000142	59.74
REWIND S000147	46.35
COMBINE 2 S000155	41.87
SCALE™ Insulin S000159	52.27
Lixilan-O-AP S000170	47.4
NCT01476475 S000191	48.92
OUTSTAND-1 S000213	33.09
PB119 S000217	26.74
NCT01001104 S000232	26.19
PIONEER 10 S000234	25.74
NCT02846233 S000236	40.91
AWARD-7 S000237	47.69
NCT01584232 S000246	28.51
NCT03235050 S000257	53.72
NCT04235959 S000277	45.83
SUSTAIN™ 3 S000329	44.53
EGO S000337	49.24
NCT00765817 S000345	42.87
NCT01029886 S000352	45.49
SUSTAIN 11 S000363	48.86
SUSTAIN 7 S000372	55.12
NCT00791479 S000376	55.09
NCT00637273 S000402	48.02
SURPASS-1 S000407	48.31
NCT00717457 S000414	46.98 100 minus male share
NCT00976937 S000415	59.9 100 minus male share
NCT00516074 S000435	44.44
ACHIEVE-3 S000438	48.59
NCT00082407 S000441	48.98
AWARD-9 S000446	42.33
NCT05579977 S000448	52.05
COMBINE 1 S000458	38.11
SUSTAIN 9 S000483	41.72
GETGOAL-L-ASIA S000488	52.09
NCT04867785 S000489	55.52
GETGOAL-S S000491	49.48
PIONEER 12 S000522	41.7
NCT00612794 S000536	40.37 100 minus male share
NCT06589765 S000558	35.68
SUSTAIN 10 S000584	43.33
NCT01175473 S000587	33.12
NCT03951753 S000593	26.5
NCT00960661 S000609	39.09
NCT00935532 S000632	32.08
NCT03555994 S000670	33.33
PREVAIL S000693	42.72
NCT02229383 S000703	52.04 100 minus male share
NCT02081118 S000719	54.01
NCT00577824 S000752	31.49
ATTAIN-2 S000754	46.93
NCT02973321 S000763	48.31
LIRAVIS S000773	71.4
NCT01149421 S000784	48.08
NCT00434954 S000790	30.36
NCT02229396 S000791	52
GetGoal-Duo1 S000792	50.22
NCT01558271 S000837	19
NCT00849017 S000852	44.88 100 minus male share
NCT01147627 S000864	36.06
NCT05759897 S000877	40.68
SUSTAIN™1 S000878	45.62
GetGoal-O S000904	48
NCT04093752 S000909	43.62
NCT01617434 S000926	43.16
NCT00135330 S000943	48.91
LIRA-Ramadan™ S000963	50.75
NCT02200991 S001003	37.5 100 minus male share
NCT00097500 S001020	34.78
ACHIEVE-5 S001044	47.07
NCT00894322 S001058	31.43
AWARD-CHN1 S001064	45.71
NCT00359762 S001097	46
LIRA-SWITCH™ S001119	40.5
AWARD-2 S001130	48.52
DURATION-NEO-2 S001157	47.12
NCT05514535 S001161	44.19
AWARD-6 S001184	52.09
GetGoal-M-Asia S001185	50.64
NCT03985293 S001191	49.21
NCT00701935 S001193	47.5
NCT01191268 S001198	46.49
LixiLan-O S001199	49.44
GETGOAL-P S001204	47.52
SUSTAIN™ 4 S001219	not reported
NCT00375492 S001222	62.37
NCT04504396 S001230	39.7
SURPASS-4 S001287	37.51
NCT00877890 S001308	42.13
SUSTAIN S001311	42.5
NCT00360334 S001323	31.49
DUAL™ V S001328	49.73
NCT04552470 S001336	13.51
NCT01003184 S001355	32.88
SOLID-DKD S001370	26.07
AWARD-CHN2 S001404	44.77
NCT00917267 S001437	not reported
GETGOAL-X S001439	46.32
NCT00299871 S001455	50.18 100 minus male share
NCT02212067 S001486	31.97 100 minus male share
SUSTAIN™ S001498	28.47
LEAD-2 S001502	41.77
NCT01620489 S001504	49.1
NCT05486065 S001555	48.69
GETGOAL-F1 S001563	55.59
SURPASS-3 S001591	44.04
NCT00460941 S001597	56.5
SURPASS-5 S001608	44.42
NCT03322631 S001634	2.1
NCT00744926 S001638	not reported
NCT00603239 S001737	40.61
PIONEER 1 S001741	49.22
NCT00641056 S001768	45.61
ELEGANT S001780	38
NCT01126580 S001786	56.26
NCT01272232 S001792	49.76
NCT00943917 S001812	50.32
SUSTAIN 8 S001847	46.19
SUSTAIN™ 5 S001872	43.83
NCT00382239 S001906	31.14 100 minus male share
SUSTAIN™ 6 S001933	39.28
SURPASS-SWITCH S001940	48.18
AGAC2 S001949	43.29
ACHIEVE-1 S001950	48.12
NCT01632163 S001963	54.65 100 minus male share
NCT00676338 S001966	40.99
NCT05086445 S001999	3.33 100 minus male share
NCT00423501 S002003	51.83
LIXILAN JP-O1 S002018	35.85
GETGOAL-L S002023	53.83
PIONEER 5 S002025	51.85
DUAL™ II Japan S002038	36.67
NCT03550378 S002039	48.8
AMPLITUDE-M S002081	46.06
NCT02288273 S002087	43.99 100 minus male share
LEAD-5 S002098	43.38
Lixilan-L-CN S002110	41.81 100 minus male share
NCT04998032 S002121	46.97
AWARD-1 S002153	41.51
GETGOAL-M S002188	58.44
NCT01425580 S002231	27.44 100 minus male share
NCT03311724 S002256	40.54
NCT05048719 S002265	40.99
PIONEER 3 S002267	47.16
NCT04466904 S002331	42
GETGOAL-MONO S002333	47.28
NCT00700817 S002361	47.07
PIONEER 8 S002369	45.96
NCT06256523 S002776	41.95
S002858 S002858	35.35
S002928 S002928	32.37
S002946 S002946	18.7 100 minus male share
S002947 S002947	35.85
S002951 S002951	36.57
NCT05654831 S002988	44.85 100 minus male share
S003009 S003009	48.75
S003023 S003023	35.05 100 minus male share
S003047 S003047	21.73 100 minus male share
S003058 S003058	33.33
S003079 S003079	not reported

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

FlagBaseline, Sex: design means range from 23.6 (DULA_SC vs DULAMACU_SC vs OTHER_ACTIVE_macupatide) to 71.4 (LIRA_SC vs VILDAGLIPTIN) percent female; threshold 15
FlagEligibility, hba1c entry range: a design requires hba1c 1000 or more while another admits only 8 or less
FlagEligibility, bmi entry range: a design requires bmi 50 or more while another admits only 35 or less
NoteOutcome assessment, time point: selected time points span 0.43 to 365.26 weeks
NoteOutcome assessment, analysis set: mixed: completers 2, full_analysis 6, modified_itt 12, other 3, randomized 9, safety 136
NoteOutcome assessment, definition: mixed: ADA 2018 level 2, glucose below 3.0 mmol/L; level 3 printed as zero in all arms 1, adverse event term hypoglycemia, threshold not stated 1, all cause deaths 1, any hypoglycemia, blood glucose below 70 mg/dL 1, Any signs or symptoms of hypoglycemia regardless of glucose 1, confirmed: severe or plasma glucose below 3.1 mmol/L 1, documented plasma glucose below 3.0 mmol/L regardless of symptoms 1, Documented symptomatic, plasma glucose 3.9 mmol/L or lower 1, glucose below 3.0 mmol/L; no severe events in any arm 1, Grade 1 or 2 hypoglycemia below 3.9 mmol/L 1, Hypoglycaemia reported as treatment emergent adverse event 1, Hypoglycemia adverse event of special interest 1, Hypoglycemia adverse event term 1, hypoglycemia adverse event term, any severity 1, hypoglycemia adverse event, definition not stated 1, hypoglycemia below 3.0 mmol/L or requiring assistance 1, Hypoglycemia preferred term, mostly mild by investigator 1, hypoglycemia reported as serious adverse event; level not stated 1, hypoglycemia requiring medical assistance 1, investigator reported symptomatic hypoglycemia 1, level 3 severe hypoglycemia 2, Major: loss of consciousness or seizure, or glucose below 3.0 mmol/L needing assistance;Minor confirmed: symptoms with glucose below 3.0 mmol/L, self treated 1, minor (symptomatic, glucose below 54 mg/dL) or major hypoglycemia 1, minor: symptomatic, glucose below 3.0 mmol/L, not major 1, minor: symptoms with glucose below 3 mmol/L, self treated or resolved 1, not stated 119, participants with serious adverse events 2, plasma glucose 54 mg/dL or lower 1, serious adverse event term hypoglycaemia 1, serious adverse events 1, Severe (ADA) or glucose confirmed below 3.1 mmol/L with symptoms 1, severe (ADA) or symptomatic with plasma glucose below 3.1 mmol/L 1, severe hypoglycemia needing assistance of another person 1, Severe hypoglycemia needing medical treatment 1, severe hypoglycemia needing third party assistance 1, severe hypoglycemia with severe cognitive impairment needing medical treatment 1, severe hypoglycemia, undefined 1, severe symptomatic hypoglycemia needing assistance 1, severe, requiring assistance of another person 2, symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery 1, symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery with carbohydrate 1, Symptomatic hypoglycemia with glucose below 60 mg/dL or symptoms without measurement 1, symptomatic hypoglycemia with plasma glucose below 3.3 mmol/L or prompt recovery with carbohydrate 1, TEAE leading to death 1, TEAE preferred term hypoglycemia, not necessarily protocol defined 1, vomiting 1, Zero implied by no hypoglycemia of any kind 1
NoteOutcome assessment, adjudicated: mixed: not stated 166, yes 2
NoteOutcome assessment, proportion method: mixed: not stated 165, observed 3
NoteOutcome assessment, intercurrent events (discontinuation): mixed: not stated 162, treatment_policy 1, while_on_treatment 5
NoteOutcome assessment, intercurrent events (rescue): mixed: not stated 165, treatment_policy 3
NoteRisk of bias, blinding: mixed: double_blind 102, open_label 59, single_blind 7
NoteRisk of bias, funding: mixed: industry 155, mixed 3, non_industry 8, not_reported 2
NoteData handling, input conversions: arms_combined 78, count_from_percent 8, nonserious_only 155, printed_denominator 26

Comparability items per trial
Trial	time weeks	analysis set	definition	instrument	adjudicated	proportion method	intercurrent events (discontinuation)	intercurrent events (rescue)	blinding	funding	start year	Eligibility
NCT03131687	30	safety	severe hypoglycemia needing assistance of another person	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 50; diet and exercise or metformin
NCT00754988	156	safety	hypoglycemia adverse event, definition not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 25 (23 Asian) to 45; metformin at least 1500 mg
NCT05407961	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	Age 18 to 70; BMI 23 to 45; HbA1c 7.0 to 10.0 on metformin or diet, 6.0 to 9.5 on DPP-4 or SGLT2 inhibitor (washed out)
NCT00518115	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2007	age 18 to 75; BMI 20 to 40; HbA1c 7 to 10 percent; drug naive or metformin
NCT01296412	26	safety	investigator reported symptomatic hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2011	age 18 to 79; HbA1c 7.0 to 11.0 percent on metformin 1500 mg or more; eGFR 60 or more
NCT00838916	164	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	age 18 or older, HbA1c 7.0 to 10.0 percent, BMI 20 to 45, creatinine clearance above 60
SURPASS-6	56	safety	not stated	not stated	yes	not stated	while_on_treatment	not stated	open_label	industry	2020	adults 18 or older; HbA1c 7.5 to 11 percent; BMI 23 to 45; basal insulin at least 30 U/day with or without up to 2 oral drugs
PIONEER 4	57	safety	not stated	not stated	not stated	not stated	while_on_treatment	treatment_policy	double_blind	industry	2016	Age 18 or older; T2D on metformin with or without SGLT2i; HbA1c 7.0 to 9.5 percent; eGFR 60 or more
NCT04965506	24	safety	glucose below 3.0 mmol/L; no severe events in any arm	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 75; HbA1c 7.0 to 10.5 percent; BMI 20 to under 40; diet or metformin
MAGNA VICTORIA	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	mixed	2015	South Asian descent; age 18 to 74; BMI 23 or more; HbA1c 6.5 to 11.0 percent
REWIND	365.26	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2011	age 50 or older with T2D; HbA1c 9.5 percent or less; BMI 23 or more; CV disease or risk factors
COMBINE 2	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2022	adults T2D on GLP-1 RA with or without oral drugs; HbA1c 7.0 to 10.0 percent
SCALE™ Insulin	58	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 or older; BMI 27 or higher; HbA1c 6.0 to 10 percent; basal insulin plus up to 2 oral drugs
Lixilan-O-AP	24.43	safety	documented plasma glucose below 3.0 mmol/L regardless of symptoms	not stated	not stated	not stated	not stated	not stated	open_label	industry	2019	adults with T2D on metformin with or without a second OAD; HbA1c 7.5 to 11 percent, or 7 to 10 percent with a non SGLT2i second OAD
NCT01476475	24	safety	Documented symptomatic, plasma glucose 3.9 mmol/L or lower	not stated	not stated	not stated	not stated	not stated	open_label	industry	2011	Adults with T2D; HbA1c 7 to 10 percent on metformin at least 1.5 g/day; insulin naive
OUTSTAND-1	32	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 19.0 to 40.0; diet and exercise only
PB119	24	safety	Severe hypoglycemia needing medical treatment	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	age 18 to 75; HbA1c 7.5 to 11.0 at screening and 7.0 to 10.5 at randomization; BMI 18.5 to 40; eGFR 60 or more; drug naive
NCT01001104	16	safety	vomiting	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	Japanese T2D age 20 to 74; BMI 18.5 to 40; HbA1c 7.0 to 9.5 percent after lead in
PIONEER 10	57	safety	not stated	not stated	yes	not stated	while_on_treatment	treatment_policy	single_blind	industry	2017	Japanese adults 20 or older; T2D; HbA1c 7.0 to 10.5 percent on one oral glucose lowering drug
NCT02846233	16	randomized	any hypoglycemia, blood glucose below 70 mg/dL	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2016	age over 21; BMI 30 or more; HbA1c above 8 percent; eGFR above 45; basal plus prandial or premixed insulin
AWARD-7	52	safety	Hypoglycaemia reported as treatment emergent adverse event	not stated	not stated	not stated	treatment_policy	treatment_policy	single_blind	industry	2012	adults with T2D and CKD stage 3 to 4 (eGFR 15 to below 60); HbA1c 7.5 to 10.5 percent on insulin; maximal ACEI or ARB; BMI 23 to 45
NCT01584232	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2012	Japanese adults 20 years or older; BMI 18.5 to less than 35 kg/m2; HbA1c 7.0 to 10.0 percent; on sulfonylurea and/or biguanide
NCT03235050	58	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 or older; BMI 25 or higher; HbA1c 7.0 to 10.5 percent; on metformin
NCT04235959	43	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	Chinese adults 20 to 70 years, HbA1c 7.0 to 10.5 diet only or 6.5 to 10.0 on one OAM, BMI 23 or more
SUSTAIN™ 3	62	safety	not stated	not stated	not stated	not stated	while_on_treatment	not stated	open_label	industry	2013	age 18 or older; T2D on stable 1 to 2 oral drugs; HbA1c 7.0 to 10.5 percent; eGFR 60 or more
EGO	16	safety	serious adverse events	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	overweight or obese adults with type 2 diabetes
NCT00765817	30	full_analysis	minor: symptoms with glucose below 3 mmol/L, self treated or resolved	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults 18 or older; insulin glargine 20 U/d or more alone or with metformin or pioglitazone; HbA1c 7.1 to 10.5 percent; BMI 45 or less
NCT01029886	26	modified_itt	not stated	not stated	not stated	not stated	while_on_treatment	not stated	open_label	industry	2010	adults 18 or older with type 2 diabetes on oral agents, HbA1c 7.1 to 11.0 percent, BMI 45 or less
SUSTAIN 11	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2018	adults; HbA1c above 7.5 to 10.0 percent on insulin glargine plus metformin
SUSTAIN 7	45	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	age 18 or older; HbA1c 7.0 to 10.5 percent; eGFR 60 or higher; metformin background
NCT00791479	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults with type 2 diabetes on no background glucose lowering drug
NCT00637273	26	modified_itt	not stated	not stated	not stated	observed	not stated	not stated	double_blind	industry	2008	age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 25 to 45; stable metformin
SURPASS-1	44	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	adults; HbA1c 7.0 to 9.5 percent; BMI 23 or higher; no glucose lowering drug in prior 90 days
NCT00717457	104	safety	adverse event term hypoglycemia, threshold not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2008	age 18 to 75; HbA1c 7 to 10 percent; BMI 25 to 45 (above 23 for Asians); metformin with or without TZD
NCT00976937	24	safety	severe symptomatic hypoglycemia needing assistance	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	age 18 to under 50; BMI 30 or more; HbA1c 7.0 to 10 percent; metformin at least 1.5 g/day
NCT00516074	12	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2007	age 18 to 75; HbA1c 6.5 to 9.5 percent; BMI 25 to 40; metformin and/or thiazolidinedione
ACHIEVE-3	57	safety	hypoglycemia reported as serious adverse event; level not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2023	adults T2D on metformin; HbA1c 7.0 to 10.5 percent
NCT00082407	52	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2003	Age 30 to 75; HbA1c 7.0 to 11.0 on metformin plus sulfonylurea; BMI 25 to 40
AWARD-9	28	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	adults with T2D on basal insulin glargine with or without metformin
NCT05579977	28	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 75; T2D cohort on metformin, HbA1c 7.0 to 10.0, BMI 23 or more; obesity cohort BMI 30 or more without diabetes
COMBINE 1	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2022	adults 18+; HbA1c 7.0-10.0%; BMI 40 or less; basal insulin 20-80 U/day; eGFR 30 or more
SUSTAIN 9	36	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	adults 18 or older (20 in Japan); HbA1c 7.0 to 10.5 percent; stable SGLT2i with or without metformin or SU
GETGOAL-L-ASIA	24	safety	symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	age 25 to 81; type 2 diabetes at least 1 year; stable basal insulin at least 10 U/day with or without sulfonylurea; HbA1c 7 to 10 percent
NCT04867785	40	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 75; HbA1c 7.0 to 10.5 percent; BMI 25 to 50; diet and exercise or stable metformin
GETGOAL-S	120	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults on sulfonylurea with or without metformin; HbA1c 7 to 10 percent
PIONEER 12	31	safety	ADA 2018 level 2, glucose below 3.0 mmol/L; level 3 printed as zero in all arms	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	adults with type 2 diabetes on metformin, HbA1c 7.0 to 10.5 percent
NCT00612794	20	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2007	Japanese T2D age 20 to 75; weight 50 kg or more; HbA1c 6.5 to 10 percent; diet or oral drugs
NCT06589765	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 75; HbA1c 7.5 to 11.0 percent; BMI 19 to 40; metformin monotherapy; eGFR 45 or more
SUSTAIN 10	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2017	adults with T2D, HbA1c 7.0 to 11.0 percent on 1 to 3 oral drugs
NCT01175473	4.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2010	age 37 to 74; HbA1c 6.5 to 9.0 percent; BMI above 20 and below 37; metformin 1.5 g/day or more
NCT03951753	32	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	age 20 to 74; BMI 25 to 45; metformin with or without one other oral agent
NCT00960661	30	other	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	age 18 or older; T2D on insulin glargine and metformin with or without sulfonylurea; HbA1c 7.0 to 10.0; BMI 25.0 (23.0 in South Korea) to 45.0; HbA1c above 7.0 after optimization
NCT00935532	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	type 2 diabetes on biguanide with or without thiazolidinedione
NCT03555994	9	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2018	adults; BMI 27 to 40; HbA1c 8.0 or lower on metformin alone
PREVAIL	20	modified_itt	severe hypoglycemia, undefined	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2014	age 30 to 80; T2D 7 years or less; A1c 6.0 to 9.5 percent off drugs or 5.5 to 9.0 on up to 2 oral drugs
NCT02229383	38	safety	minor: symptomatic, glucose below 3.0 mmol/L, not major	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	adults; insulin glargine 20 U/d or more with or without metformin; HbA1c 7.0 to 10.5 percent at randomization
NCT02081118	22	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 to under 75; metformin; HbA1c 7.0 to 10 percent; BMI under 40
NCT00577824	24	full_analysis	Any signs or symptoms of hypoglycemia regardless of glucose	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 20 to 75; HbA1c 7.0 to 10.0 percent JDS; weight 50 kg or more; sulfonylurea based oral therapy
ATTAIN-2	74	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2023	adults with type 2 diabetes; BMI 27 or higher; HbA1c 7.0 to 10.0 percent
NCT02973321	26.4	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2016	adults with type 2 diabetes and overweight or obesity
LIRAVIS	2	randomized	not stated	not stated	not stated	not stated	not stated	not stated	single_blind	not_reported	2016	adults with type 2 diabetes on one or two oral drugs; HbA1c 7 percent or more; eGFR 30 or more; incretin naive
NCT01149421	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2010	adults 18 or older; HbA1c 7 to 9.5 percent; stable oral agents
NCT00434954	26	full_analysis	not stated	not stated	not stated	observed	not stated	not stated	open_label	industry	2007	adults with T2D on metformin, HbA1c 6.5 to 10.0 percent
NCT02229396	104	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 or older; HbA1c 8.0 to 12.0 percent on metformin 1500 mg/d or more
GetGoal-Duo1	24.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	T2D on metformin 1.5 g or more with or without SU, glinide or TZD, HbA1c 7 to 10, BMI over 20; HbA1c 7 to 9 after run in
NCT01558271	56.29	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	Japanese; age 20 or more; BMI 18.5 to 35; HbA1c 7.0 to 10.0 percent; OAM naive or OAM stopped
NCT00849017	164	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	age 18 or older; HbA1c 7.0 to 10.0 percent; BMI 20 to 45; diet and exercise only
NCT01147627	48	randomized	not stated	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2010	newly diagnosed drug naive T2D; age 30 to 70; HbA1c 7 to 10 percent; BMI 20 to 35
NCT05759897	16	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2023	age 18 to 75; BMI 19.0 to 40.0; HbA1c 7.5 to 11.0 on stable metformin
SUSTAIN™1	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; drug naive on diet and exercise; eGFR 30 or more
GetGoal-O	24.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2013	age 70 or older; type 2 diabetes uncontrolled on basal insulin and/or oral drugs; eGFR 30 or higher
NCT04093752	44	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2019	adults with T2D on metformin with or without sulfonylurea
NCT01617434	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	age 18 to 80; HbA1c 7.0 to 10.0 percent; BMI 20 to 45; basal insulin analogue 20 U or more with or without metformin
NCT00135330	20	randomized	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2005	age 18 to 75; BMI 25 to 40; HbA1c 6.8 to 10.0 percent; stable metformin only
LIRA-Ramadan™	30	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	age 18 to 80; HbA1c 7 to 10 percent; BMI 20 or more; metformin plus sulfonylurea; intent to fast in Ramadan
NCT02200991	4.43	safety	severe hypoglycemia needing third party assistance	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	age 20 to 75; T2D 5 years or more; HbA1c 7.0 to 10.0; FBG 180 mg/dL or less; stable glargine
NCT00097500	64	safety	Hypoglycemia adverse event term	not stated	not stated	not stated	not stated	not stated	open_label	industry	2004	age 30 to 75; HbA1c 6.5 to 9.5 percent; BMI 25 to 40; on metformin
ACHIEVE-5	42	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2023	adults with T2D on insulin glargine with or without metformin or SGLT2 inhibitor
NCT00894322	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	single_blind	industry	2009	adults with T2D on diet and exercise, metformin, TZD or both
AWARD-CHN1	26	safety	severe, requiring assistance of another person	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 10.5 percent OAM naive or 6.5 to 10.0 percent on OAM monotherapy
NCT00359762	234.81	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2006	age 18 to 85; BMI 25 to below 40; HbA1c 6.5 to below 9.0 percent on maximum tolerated metformin
LIRA-SWITCH™	27	safety	confirmed: severe or plasma glucose below 3.1 mmol/L	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2013	age 18 or more; HbA1c 7.5 to 9.5 percent; BMI 20 or more; on sitagliptin 100 mg and metformin for 90 days or more
AWARD-2	78	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2010	type 2 diabetes on metformin and glimepiride
DURATION-NEO-2	28	safety	minor (symptomatic, glucose below 54 mg/dL) or major hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2013	age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 45 or lower; metformin 1500 mg or more
NCT05514535	45	safety	level 3 severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2022	adults with T2D, BMI 25 or more, HbA1c 7 to 10 percent, basal insulin up to 40 U/day plus metformin with or without SGLT2i
AWARD-6	30	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2012	adults; HbA1c 7 to 10 percent; metformin 1500 mg/day or more
GetGoal-M-Asia	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2010	Asian adults with type 2 diabetes on metformin with or without sulfonylurea
NCT03985293	20	safety	TEAE preferred term hypoglycemia, not necessarily protocol defined	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	age 18 to 75; HbA1c 7 to 10.5 percent; BMI 22.5 (Asia) or 24.5 to 45.4; metformin or diet and exercise
NCT00701935	26.07	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults with T2D on metformin
NCT01191268	56	safety	participants with serious adverse events	not stated	not stated	not stated	not stated	not stated	open_label	industry	2010	adults with type 2 diabetes on conventional insulin with or without metformin
LixiLan-O	30.29	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	adults; HbA1c 7.5 to 10% on metformin or 7 to 9% on metformin plus second OAD; 7 to 10% after run in
GETGOAL-P	132	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	type 2 diabetes on pioglitazone 30 mg or more with or without metformin; HbA1c 7 percent or more
SUSTAIN™ 4	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	adults with T2D, insulin naive, on metformin with or without SU; HbA1c 7.0 to 10.0 percent
NCT00375492	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	type 2 diabetes; weight loss trial
NCT04504396	24	safety	severe hypoglycemia with severe cognitive impairment needing medical treatment	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	age 18 to 75; HbA1c 7.0 to 10.5 percent; BMI 40 or lower; eGFR 60 or higher; metformin monotherapy at least 1000 mg
SURPASS-4	108	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2018	age 18 or older; HbA1c 7.5 to 10.5 percent; BMI 25 or more; increased cardiovascular risk; 1 to 3 oral agents
NCT00877890	24	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 25 to 45
SUSTAIN	35	safety	Severe (ADA) or glucose confirmed below 3.1 mmol/L with symptoms	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	Adults 18 or older, HbA1c 7.0 to 10.5 percent on metformin monotherapy, eGFR 60 or more
NCT00360334	26	full_analysis	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2006	BMI above 27; HbA1c 7.5 to 10.0 percent; 2 or 3 oral drugs; at least one CV risk factor
DUAL™ V	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2013	T2D uncontrolled on insulin glargine 20 to 50 U plus metformin
NCT04552470	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	Japanese adults 20 to 70, diet and exercise only, HbA1c 7 to 10.5 percent, BMI 22.5 to 45.4
NCT01003184	26	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	age 18 or older; HbA1c 7.1 to 10.0 percent; BMI 25 to 45; metformin with or without SU
SOLID-DKD	18	safety	level 3 severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 75; T2D with UACR 300 to below 3000 mg/g; eGFR 30 or more; HbA1c 6.5 to 10; BMI 20 to 40
AWARD-CHN2	52	safety	severe, requiring assistance of another person	not stated	not stated	not stated	not stated	not stated	open_label	industry	2012	age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 11.0 percent on metformin and/or sulfonylurea
NCT00917267	36	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	Asian adults 20 or older; HbA1c 7 to 11; BMI 21 to 35; on oral drugs
GETGOAL-X	116	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2008	age 21 to 84; HbA1c 7 to 10 percent; metformin at least 1.5 g/day
NCT00299871	13.43	safety	symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery with carbohydrate	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 30 to 75; HbA1c 7.0 to below 9.0 percent on metformin at least 1000 mg/day
NCT02212067	17	randomized	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 to 64; HbA1c 6.5 to 9.0 percent; BMI 20 to 35; diet and exercise or metformin
SUSTAIN™	62	safety	severe (ADA) or symptomatic with plasma glucose below 3.1 mmol/L	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	Japanese adults 20 or older; HbA1c 7.0 to 10.5 percent; diet and exercise or OAD monotherapy; eGFR 30 or more
LEAD-2	104.28	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 18 to 80; HbA1c 7 to 11 percent on one OAD or 7 to 10 on combination; BMI 40 or less; no recent insulin
NCT01620489	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	type 2 diabetes; eGFR 30 to 59 mL/min/1.73m2 (MDRD); oral drugs and/or insulin
NCT05486065	49	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 64; HbA1c 7.0 to 10.5; BMI 27 or more; on metformin
GETGOAL-F1	112	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults with T2D on metformin
SURPASS-3	56	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2019	insulin naive; HbA1c 7.0 to 10.5 percent; BMI at least 25; metformin with or without SGLT2i; eGFR above 45
NCT00460941	8	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2007	age 18 to 75; HbA1c 7.0 to 9.5 percent on metformin; BMI above 25 to 45
SURPASS-5	44	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	HbA1c 7.0 to 10.5 percent; BMI 23 or higher; insulin glargine above 0.25 U/kg or 20 U daily with or without metformin
NCT03322631	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	Japanese adults 20 to 70; T2D 1 year or more on diet or metformin or DPP-4 inhibitor (washed out); BMI 20 to 35
NCT00744926	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 18 to 80; drug naive; HbA1c 6.5 to 10 percent; BMI 25 to 45
NCT00603239	26	safety	participants with serious adverse events	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	type 2 diabetes on a thiazolidinedione with or without metformin
PIONEER 1	31	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2016	adults with type 2 diabetes on diet and exercise only; HbA1c 7.0 to 9.5 percent
NCT00641056	26	modified_itt	not stated	not stated	not stated	observed	not stated	not stated	open_label	industry	2008	age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 25 to 45; metformin with or without sulfonylurea
ELEGANT	26	randomized	Grade 1 or 2 hypoglycemia below 3.9 mmol/L	not stated	not stated	not stated	not stated	not stated	open_label	industry	2012	age 18 to 75; BMI 25 or more; HbA1c 6.5 to 8.5 percent; insulin 3 to 16 months with 4 percent weight gain
NCT01126580	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2010	type 2 diabetes on diet and exercise or one oral drug; registry gives no ranges
NCT01272232	68	safety	hypoglycemia adverse event term, any severity	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2011	adults with T2D, BMI 27 or more, HbA1c 7.0 to 10.0 percent, diet alone or up to 3 oral drugs
NCT00943917	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	age 18 to 70; HbA1c 7 to 10 percent; BMI 40 or less; stable metformin 3 months
SUSTAIN 8	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 or older; HbA1c 7.0 to 10.5 percent; eGFR 60 or higher; metformin 1500 mg or maximum tolerated
SUSTAIN™ 5	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; stable basal insulin with or without metformin; eGFR 30 or more
NCT00382239	12	full_analysis	Hypoglycemia preferred term, mostly mild by investigator	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 20 to 75; HbA1c 7 to 10 percent on sulfonylurea based therapy; weight 50 kg or more
SUSTAIN™ 6	109	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2013	T2D HbA1c 7.0 or more; age 50 or more with CVD, CHF or CKD stage 3 or more, or age 60 or more with CV risk factor
SURPASS-SWITCH	44	safety	all cause deaths	not stated	not stated	not stated	not stated	not stated	open_label	industry	2022	age 18 or older; HbA1c 7.0 to 9.5 percent; BMI 25 or more; stable dulaglutide 0.75 or 1.5 mg
AGAC2	0.43	randomized	not stated	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2011	age over 20, T2DM over 2 years, A1C 8 to 12 percent, premixed insulin twice daily over 0.6 U/kg/day
ACHIEVE-1	42	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2023	adults with type 2 diabetes on diet and exercise alone; HbA1c 7.0 to 9.5 percent
NCT01632163	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	adults; T2D at least 1 year; HbA1c 7 to 10.5 at screening, 7 to 9.5 after run in; basal insulin at least 15 U
NCT00676338	26	full_analysis	Major: loss of consciousness or seizure, or glucose below 3.0 mmol/L needing assistance;Minor confirmed: symptoms with glucose below 3.0 mmol/L, self treated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults, HbA1c 7.1 to 11.0 percent, BMI 23 to 45 kg/m2, drug naive
NCT05086445	14	safety	Hypoglycemia adverse event of special interest	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	Japanese; age 20 to 70; BMI 20 to 35; HbA1c 7.0 to 10.0 diet only or 6.5 to 9.0 on one OAM, withdrawn 28 days
NCT00423501	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2007	age 18 to 75; metformin 1500 mg or more; HbA1c 7 to 9.5 percent; BMI 25 to 45
LIXILAN JP-O1	52.43	safety	TEAE leading to death	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	insulin naive Japanese adults; HbA1c 7.5 to 10%; FPG 13.8 mmol/L or less; one or two OADs
GETGOAL-L	125	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults; HbA1c 7.0 to 10.0 percent; stable basal insulin with or without metformin
PIONEER 5	31	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2016	type 2 diabetes; HbA1c 7.0 to 9.5 percent; moderate renal impairment
DUAL™ II Japan	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2016	Japanese adults; BMI 23 kg/m2 or more; HbA1c 7.5 to 11.0 percent; basal or premix insulin 20 to 50 U with metformin
NCT03550378	8.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2018	age 18 to 84; BMI 25 to 45; eGFR 30 to 59; HbA1c 6.5 to 10.5 percent
AMPLITUDE-M	56	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	type 2 diabetes on diet and exercise, HbA1c 7 to 10 percent, no glucose lowering drug in prior 3 months
NCT02288273	14	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 to 75; T2D on metformin 1500 mg or more; HbA1c 7.0 to 10.0 percent; BMI 45 or less
LEAD-5	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 18 to 80; HbA1c 7.5 to 10 on monotherapy or 7 to 10 on combination; BMI 45 or lower
Lixilan-L-CN	30.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2019	Chinese adults; HbA1c 7.0 to 10.5 percent; basal insulin 10 to 25 U/day with up to 2 oral drugs; FPG at most 8.9 mmol/L
NCT04998032	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 75; metformin monotherapy; HbA1c 7.5 to 10.5 at randomization; BMI 18.5 to 40; eGFR 60 or higher
AWARD-1	56	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2010	adults with type 2 diabetes on metformin and pioglitazone
GETGOAL-M	76.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	type 2 diabetes on metformin 1.5 g/day or more for 3 months; HbA1c 7 to 10 percent; FPG 13.9 mmol/L or less
NCT01425580	18	other	not stated	not stated	not stated	not stated	not stated	not stated	single_blind	mixed	2012	type 2 diabetes; HbA1c 45 to 97 mmol/mol; subclinical LV dysfunction on echocardiography; BMI 40 or less
NCT03311724	16	modified_itt	plasma glucose 54 mg/dL or lower	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 45; diet or stable metformin
NCT05048719	28	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	adults with type 2 diabetes, HbA1c 7.0 to 10.5 percent, BMI 23 or more, diet or metformin
PIONEER 3	83	safety	serious adverse event term hypoglycaemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2016	adults with T2D; HbA1c 7.0 to 10.5 percent; metformin with or without sulfonylurea
NCT04466904	20	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	age 18 to 75; T2D on diet and exercise or stable metformin; HbA1c 7.5 to 11.0 percent; BMI 20 to 35
GETGOAL-MONO	12.43	safety	symptomatic hypoglycemia with plasma glucose below 3.3 mmol/L or prompt recovery with carbohydrate	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 20 to 85; HbA1c 7.0 to 10.0 percent; no glucose lowering drug for 3 months
NCT00700817	52	other	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2008	age 18 to 80; HbA1c 7.5 to 10%; BMI 45 or less; metformin 1500 mg/day or more for 3 months
PIONEER 8	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	adults with type 2 diabetes on basal, premixed or basal bolus insulin with or without metformin
NCT06256523	29	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 65; HbA1c 7.0 to 10.0 percent; BMI 18.5 to 35; eGFR 60 or more
S002858	24	randomized	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry		T2D age over 35; clinical CKD; eGFR above 30 mL/min; stable ACE inhibitor or ARB
S002928	24	safety	hypoglycemia below 3.0 mmol/L or requiring assistance	not stated	not stated	not stated	not stated	not stated	single_blind	non_industry	2022	age 18 to 65; BMI 50 or more; type 2 diabetes
S002946	26	randomized	Zero implied by no hypoglycemia of any kind	not stated	not stated	not stated	not stated	not stated	open_label	not_reported	2020	age over 20; T2D on liraglutide 0.6 or 0.9 mg; no new diabetes drug for 3 months
S002947	25	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 65; HbA1c 7.0 to 10.5 percent; BMI 20 to 35; diet or one oral agent washed out
S002951	16	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2022	age 18 to 65; BMI 25 or more; HbA1c 7.0 to 10.0 percent; lifestyle or one OAD
NCT05654831	4.86	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	MAD: age 18 to 70; BMI 24 to 40; HbA1c 7.0 to 10.5 percent; T2DM on metformin or lifestyle
S003009	24	completers	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2023	age 18 or more; HbA1c 7.0 to 10.0 percent; eGFR 30 to 90; UACR above 30 to 5000 mg/g
S003023	0.43	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	single_blind	non_industry		age 20 to 80, T2D not on insulin, elective CABG or valve surgery with cardiopulmonary bypass
S003047	6.57	safety	Symptomatic hypoglycemia with glucose below 60 mg/dL or symptoms without measurement	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 20 to 75; HbA1c 7.0 to 10.0 percent; BMI 35 or less; sulfonylurea with or without metformin
S003058	12	completers	not stated	not stated	not stated	not stated	not stated	not stated	open_label	non_industry		age 20 to 90; HbA1c 7.0 to 10.0 percent; on insulin glargine plus sitagliptin 50 mg at least 8 weeks
S003079	5	safety	hypoglycemia requiring medical assistance	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2010	age 18 to 80, HbA1c 7.5 to 12 percent, BMI 21 to 35, T2D at least 6 months

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Events / N	Flags	Source
NCT03131687	A1	PLACEBO	30	arm, events	1 / 51		R0016215:Table 3
NCT03131687	A2+A3+A4+A5	TIRZ_SC	30	arm, events	28 / 213	arms_combined	R0016215:Table 3
NCT03131687	A6	DULA_SC	30	arm, events	5 / 54		R0016215:Table 3
NCT00754988	A2+A3	TASP_SC	156	arm, events	132 / 388	arms_combined	R0022521:Table 2
NCT00754988	A4	SITAGLIPTIN	156	arm, events	12 / 185		R0022521:Table 2
NCT05407961	A1	OTHER_ACTIVE_macupatide	12	arm, events	1 / 15		R0015193:Table 2
NCT05407961	A2	DULA_SC	12	arm, events	2 / 29		R0015193:Table 2
NCT05407961	A3	DULAMACU_SC	12	arm, events	2 / 28		R0015193:Table 2
NCT00518115	A1	PLACEBO	24	arm, events	1 / 52	nonserious_only	registry:adverse_events
NCT00518115	A10+A3+A4+A5+A6+A7+A8+A9	ALBI_SC	24	arm, events	43 / 274	nonserious_only;arms_combined	registry:adverse_events
NCT00518115	A2	EXEN_SC	24	arm, events	6 / 35	nonserious_only	registry:adverse_events
NCT01296412	A1	SITAGLIPTIN	26	arm, events	6 / 326		R0026295:Table 3
NCT01296412	A2	LIRA_SC	26	arm, events	21 / 327		R0026295:Table 3
NCT00838916	A1	ALBI_SC	164	arm, events	27 / 516	nonserious_only	registry:adverse_events
NCT00838916	A2	INS_GLARGINE	164	arm, events	13 / 263	nonserious_only	registry:adverse_events
SURPASS-6	A1+A2+A3	TIRZ_SC	56	arm, events	62 / 717	arms_combined	R0009666:Table 3
SURPASS-6	A4	INS_LISPRO	56	arm, events	4 / 711		R0009666:Table 3
PIONEER 4	A1	SEMA_PO	57	arm, events	25 / 285		R0015836:Table 3
PIONEER 4	A2	LIRA_SC	57	arm, events	13 / 284		R0015836:Table 3
PIONEER 4	A3	PLACEBO	57	arm, events	3 / 142		R0015836:Table 3
NCT04965506	A1+A2+A3	MAZD_SC	24	arm, events	21 / 149	arms_combined	R0012443:Table 2
NCT04965506	A4	DULA_SC	24	arm, events	7 / 50		R0012443:Table 2
NCT04965506	A5	PLACEBO	24	arm, events	1 / 51		R0012443:Table 2
MAGNA VICTORIA	A1	LIRA_SC	26	arm, events	6 / 22	count_from_percent	R0020542:Results
MAGNA VICTORIA	A2	PLACEBO	26	arm, events	2 / 25	count_from_percent	R0020542:Results
REWIND	A1	PLACEBO	365.26	arm, events	154 / 4,952	nonserious_only	registry:adverse_events
REWIND	A2	DULA_SC	365.26	arm, events	325 / 4,949	nonserious_only	registry:adverse_events
COMBINE 2	A1	ICOSEMA_SC	57	arm, events	18 / 342		R0005851:Table 4
COMBINE 2	A2	SEMA_SC	57	arm, events	22 / 341		R0005851:Table 4
SCALE™ Insulin	A1	LIRA_SC	58	arm, events	32 / 198		R0024063:Table 3
SCALE™ Insulin	A2	PLACEBO	58	arm, events	12 / 198		R0024063:Table 3
Lixilan-O-AP	A1	IGLARLIXI_SC	24.43	arm, events	21 / 351		R0013321:Table 3
Lixilan-O-AP	A2	INS_GLARGINE	24.43	arm, events	1 / 350		R0013321:Table 3
Lixilan-O-AP	A3	LIXI_SC	24.43	arm, events	19 / 177		R0013321:Table 3
NCT01476475	A1	IGLARLIXI_SC	24	arm, events	4 / 161		R0021236:Table 2
NCT01476475	A2	INS_GLARGINE	24	arm, events	1 / 162		R0021236:Table 2
OUTSTAND-1	A1+A2+A3	SAFIGL_PO	32	arm, events	38 / 212	arms_combined	R0011607:Table 3
OUTSTAND-1	A4	PLACEBO	32	arm, events	0 / 72		R0011607:Table 3
PB119	A1	VISEPE_SC	24	arm, events	8 / 137		R0011471:Table 4
PB119	A2	PLACEBO	24	arm, events	0 / 136		R0011471:Table 4
NCT01001104	A1	PLACEBO	16	arm, events	0 / 37	nonserious_only	registry:adverse_events
NCT01001104	A2+A3+A4	DULA_SC	16	arm, events	1 / 108	nonserious_only;arms_combined	registry:adverse_events
PIONEER 10	A1+A2+A3	SEMA_PO	57	arm, events	13 / 393	arms_combined	R0018421:Table 2
PIONEER 10	A4	DULA_SC	57	arm, events	1 / 65		R0018421:Table 2
NCT02846233	A1	DULA_SC	16	arm, events	1 / 12		R0028441:Table 5
NCT02846233	A2	OTHER_ACTIVE_basal_bolus_insulin	16	arm, events	0 / 10		R0028441:Table 5
AWARD-7	A1	INS_GLARGINE	52	arm, events	9 / 194		R0017387:Table 2
AWARD-7	A2+A3	DULA_SC	52	arm, events	42 / 383	arms_combined	R0017387:Table 2
NCT01584232	A1	DULA_SC	26	arm, events	9 / 181		R0016159:Table 3
NCT01584232	A2	INS_GLARGINE	26	arm, events	2 / 180		R0016159:Table 3
NCT03235050	A1	PLACEBO	58	arm, events	5 / 112	nonserious_only	registry:adverse_events
NCT03235050	A2	LIRA_SC	58	arm, events	3 / 110	nonserious_only	registry:adverse_events
NCT03235050	A3+A4+A5	COTA_SC	58	arm, events	104 / 612	nonserious_only;arms_combined	registry:adverse_events
NCT04235959	A1	PLACEBO	43	arm, events	0 / 4	nonserious_only	registry:adverse_events
NCT04235959	A2+A3	TIRZ_SC	43	arm, events	1 / 20	nonserious_only;arms_combined	registry:adverse_events
SUSTAIN™ 3	A1	SEMA_SC	62	arm, events	29 / 406	nonserious_only	registry:adverse_events
SUSTAIN™ 3	A2	EXENER_SC	62	arm, events	25 / 407	nonserious_only	registry:adverse_events
EGO	A1+A2+A3	DULA_SC	16	arm, events	11 / 196	nonserious_only;arms_combined	registry:adverse_events
EGO	A4	PLACEBO	16	arm, events	2 / 66	nonserious_only	registry:adverse_events
NCT00765817	A1	EXEN_SC	30	arm, events	25 / 138		R0027069:Table 3
NCT00765817	A2	PLACEBO	30	arm, events	5 / 123		R0027069:Table 3
NCT01029886	A1	EXENER_SC	26	arm, events	17 / 461		R0016299:Table 3
NCT01029886	A2	LIRA_SC	26	arm, events	48 / 451		R0016299:Table 3
SUSTAIN 11	A1	SEMA_SC	52	arm, events	50 / 874		R0022346:Table 3
SUSTAIN 11	A2	INS_ASPART	52	arm, events	5 / 874		R0022346:Table 3
SUSTAIN 7	A1+A2	SEMA_SC	45	arm, events	61 / 601	nonserious_only;arms_combined	registry:adverse_events
SUSTAIN 7	A3+A4	DULA_SC	45	arm, events	41 / 600	nonserious_only;arms_combined	registry:adverse_events
NCT00791479	A1+A2+A3+A4+A5	DULA_SC	12	arm, events	3 / 135	nonserious_only;arms_combined	registry:adverse_events
NCT00791479	A6	PLACEBO	12	arm, events	2 / 32	nonserious_only	registry:adverse_events
NCT00637273	A1	EXENER_SC	26	arm, events	18 / 170	count_from_percent	R0024240:Table 4
NCT00637273	A2	SITAGLIPTIN	26	arm, events	3 / 172	count_from_percent	R0024240:Table 4
NCT00637273	A3	PIOGLITAZONE	26	arm, events	5 / 172	count_from_percent	R0024240:Table 4
SURPASS-1	A1+A2+A3	TIRZ_SC	44	arm, events	14 / 363	arms_combined	R0007531:Supplement Table S2
SURPASS-1	A4	PLACEBO	44	arm, events	2 / 115		R0007531:Supplement Table S2
NCT00717457	A1+A2	TASP_SC	104	arm, events	275 / 797	arms_combined	R0013639:Table 2
NCT00717457	A3	EXEN_SC	104	arm, events	60 / 392		R0013639:Table 2
NCT00976937	A1	LIXI_SC	24	arm, events	7 / 158		R0012687:Table 2
NCT00976937	A2	SITAGLIPTIN	24	arm, events	0 / 161		R0012687:Table 2
NCT00516074	A1	EXEN_SC	12	arm, events	2 / 28	nonserious_only	registry:adverse_events
NCT00516074	A2	PLACEBO	12	arm, events	2 / 26	nonserious_only	registry:adverse_events
ACHIEVE-3	A1+A2	ORFO_PO	57	arm, events	142 / 847	nonserious_only;arms_combined	registry:adverse_events
ACHIEVE-3	A3+A4	SEMA_PO	57	arm, events	77 / 851	nonserious_only;arms_combined	registry:adverse_events
NCT00082407	A1	EXEN_SC	52	arm, events	38 / 255		R0025791:Table 3
NCT00082407	A2	INS_PREMIX	52	arm, events	8 / 250		R0025791:Table 3
AWARD-9	A1	DULA_SC	28	arm, events	9 / 150	nonserious_only	registry:adverse_events
AWARD-9	A2	PLACEBO	28	arm, events	0 / 150	nonserious_only	registry:adverse_events
NCT05579977	A1+A8	PLACEBO	28	arm, events	2 / 139	arms_combined	R0004106:Table 2
NCT05579977	A10+A11+A12+A13+A2+A3+A4+A5+A6+A9	LOTI_PO	28	arm, events	114 / 690	arms_combined	R0004106:Table 2
NCT05579977	A7	SEMA_PO	28	arm, events	6 / 73		R0004106:Table 2
COMBINE 1	A1	ICOSEMA_SC	57	arm, events	68 / 646	nonserious_only	registry:adverse_events
COMBINE 1	A2	INS_ICODEC	57	arm, events	17 / 645	nonserious_only	registry:adverse_events
SUSTAIN 9	A1	SEMA_SC	36	arm, events	14 / 151	nonserious_only	registry:adverse_events
SUSTAIN 9	A2	PLACEBO	36	arm, events	3 / 151	nonserious_only	registry:adverse_events
GETGOAL-L-ASIA	A1	LIXI_SC	24	arm, events	28 / 154		R0022626:Table 2
GETGOAL-L-ASIA	A2	PLACEBO	24	arm, events	3 / 157		R0022626:Table 2
NCT04867785	A1	PLACEBO	40	arm, events	1 / 45	nonserious_only	registry:adverse_events
NCT04867785	A2	DULA_SC	40	arm, events	4 / 46	nonserious_only	registry:adverse_events
NCT04867785	A3+A4+A5+A6+A7+A8	RETA_SC	40	arm, events	13 / 190	nonserious_only;arms_combined	registry:adverse_events
GETGOAL-S	A1	PLACEBO	120	arm, events	15 / 286	nonserious_only	registry:adverse_events
GETGOAL-S	A2	LIXI_SC	120	arm, events	61 / 573	nonserious_only	registry:adverse_events
PIONEER 12	A1+A2+A3	SEMA_PO	31	arm, events	63 / 1,082	arms_combined	R0019776:Table 3
PIONEER 12	A4	SITAGLIPTIN	31	arm, events	1 / 359		R0019776:Table 3
NCT00612794	A1	PLACEBO	20	arm, events	1 / 10	printed_denominator	R0027116:p5
NCT00612794	A3	EXENER_SC	20	arm, events	1 / 9	printed_denominator	R0027116:p5
NCT06589765	A1+A2+A3	SAFIGL_PO	52	arm, events	156 / 608	arms_combined	R0029347:Table 3
NCT06589765	A4	DAPAGLIFLOZIN	52	arm, events	4 / 202		R0029347:Table 3
SUSTAIN 10	A1	SEMA_SC	35	arm, events	29 / 290	nonserious_only	registry:adverse_events
SUSTAIN 10	A2	LIRA_SC	35	arm, events	23 / 287	nonserious_only	registry:adverse_events
NCT01175473	A1	LIXI_SC	4.43	arm, events	8 / 77		R0022723:Table 3
NCT01175473	A2	LIRA_SC	4.43	arm, events	5 / 71		R0022723:Table 3
NCT03951753	A1	TIRZ_SC	32	arm, events	3 / 45	nonserious_only	registry:adverse_events
NCT03951753	A2	SEMA_SC	32	arm, events	5 / 44	nonserious_only	registry:adverse_events
NCT03951753	A3	PLACEBO	32	arm, events	1 / 28	nonserious_only	registry:adverse_events
NCT00960661	A1	EXEN_SC	30	arm, events	39 / 316		R0016788:Supplement Table 4
NCT00960661	A2	INS_LISPRO	30	arm, events	3 / 321		R0016788:Supplement Table 4
NCT00935532	A1	EXENER_SC	26	arm, events	18 / 215	nonserious_only	registry:adverse_events
NCT00935532	A2	INS_GLARGINE	26	arm, events	5 / 212	nonserious_only	registry:adverse_events
NCT03555994	A1	PLACEBO	9	arm, events	0 / 11	nonserious_only	registry:adverse_events
NCT03555994	A2	LIRA_SC	9	arm, events	1 / 10	nonserious_only	registry:adverse_events
NCT03555994	A3	COTA_SC	9	arm, events	1 / 9	nonserious_only	registry:adverse_events
PREVAIL	A1	STANDARD_CARE	20	arm, events	0 / 33		R0010144:Supplementary Table 1
PREVAIL	A2	INS_LISPRO	20	arm, events	0 / 35		R0010144:Supplementary Table 1
PREVAIL	A3	EXEN_SC	20	arm, events	1 / 35		R0010144:Supplementary Table 1
NCT02229383	A1	EXENER_SC	38	arm, events	1 / 233		R0014763:Table 3
NCT02229383	A2	PLACEBO	38	arm, events	3 / 231		R0014763:Table 3
NCT02081118	A1	PLACEBO	22	arm, events	2 / 51		R0009733:Table 3
NCT02081118	A2+A3+A4	EFPE_SC	22	arm, events	38 / 157	printed_denominator;arms_combined	R0009733:Table 3
NCT00577824	A1	PLACEBO	24	arm, events	1 / 36		R0018881:Table 2
NCT00577824	A2+A3	EXEN_SC	24	arm, events	15 / 145	arms_combined	R0018881:Table 2
ATTAIN-2	A1	PLACEBO	74	arm, events	24 / 630	nonserious_only	registry:adverse_events
ATTAIN-2	A2+A3+A4	ORFO_PO	74	arm, events	183 / 983	nonserious_only;arms_combined	registry:adverse_events
NCT02973321	A1	PLACEBO	26.4	arm, events	2 / 33	nonserious_only	registry:adverse_events
NCT02973321	A5	LIRA_SC	26.4	arm, events	1 / 67	nonserious_only	registry:adverse_events
LIRAVIS	A1	LIRA_SC	2	arm, events	1 / 7		R0055449:Table 5
LIRAVIS	A2	VILDAGLIPTIN	2	arm, events	1 / 7		R0055449:Table 5
NCT01149421	A1+A2	DULA_SC	26	arm, events	30 / 505	nonserious_only;arms_combined	registry:adverse_events
NCT01149421	A3	PLACEBO	26	arm, events	11 / 250	nonserious_only	registry:adverse_events
NCT00434954	A1	EXEN_SC	26	arm, events	18 / 248	count_from_percent	R0027127:Results
NCT00434954	A2	INS_PREMIX	26	arm, events	2 / 246	nonserious_only	registry:adverse_events
NCT02229396	A1	DAPAEXEN_SC	104	arm, events	8 / 231	nonserious_only	registry:adverse_events
NCT02229396	A2	EXENER_SC	104	arm, events	12 / 231	nonserious_only	registry:adverse_events
NCT02229396	A3	DAPAGLIFLOZIN	104	arm, events	7 / 233	nonserious_only	registry:adverse_events
GetGoal-Duo1	A1	PLACEBO	24.43	arm, events	3 / 223	nonserious_only	registry:adverse_events
GetGoal-Duo1	A2	LIXI_SC	24.43	arm, events	21 / 223	nonserious_only	registry:adverse_events
NCT01558271	A1	DULA_SC	56.29	arm, events	5 / 281	nonserious_only	registry:adverse_events
NCT01558271	A2	LIRA_SC	56.29	arm, events	1 / 141	nonserious_only	registry:adverse_events
NCT00849017	A1	PLACEBO	164	arm, events	1 / 105	nonserious_only	registry:adverse_events
NCT00849017	A2+A3	ALBI_SC	164	arm, events	8 / 204	nonserious_only;arms_combined	registry:adverse_events
NCT01147627	A1	EXEN_SC	48	arm, events	15 / 142	nonserious_only	registry:adverse_events
NCT01147627	A2	INS_PREMIX	48	arm, events	1 / 138	nonserious_only	registry:adverse_events
NCT01147627	A3	PIOGLITAZONE	48	arm, events	1 / 136	nonserious_only	registry:adverse_events
NCT05759897	A1	PLACEBO	16	arm, events	0 / 39	printed_denominator	R0002101:Table 3
NCT05759897	A2+A3+A4+A5	SAFIGL_PO	16	arm, events	14 / 155	printed_denominator;arms_combined	R0002101:Table 3
SUSTAIN™1	A1+A2	SEMA_SC	35	arm, events	14 / 259	nonserious_only;arms_combined	registry:adverse_events
SUSTAIN™1	A3	PLACEBO	35	arm, events	2 / 129	nonserious_only	registry:adverse_events
GetGoal-O	A1	LIXI_SC	24.43	arm, events	10 / 176	nonserious_only	registry:adverse_events
GetGoal-O	A2	PLACEBO	24.43	arm, events	1 / 174	nonserious_only	registry:adverse_events
NCT04093752	A1+A2+A3	TIRZ_SC	44	arm, events	84 / 687	nonserious_only;arms_combined	registry:adverse_events
NCT04093752	A4	INS_GLARGINE	44	arm, events	3 / 230	nonserious_only	registry:adverse_events
NCT01617434	A1	LIRA_SC	27	arm, events	20 / 226		R0026247:Table 3
NCT01617434	A2	PLACEBO	27	arm, events	2 / 225		R0026247:Table 3
NCT00135330	A1	EXEN_SC	20	arm, events	10 / 45	nonserious_only	registry:adverse_events
NCT00135330	A2	EXENROSI_SC	20	arm, events	9 / 47	nonserious_only	registry:adverse_events
NCT00135330	A3	ROSIGLITAZONE	20	arm, events	0 / 45	nonserious_only	registry:adverse_events
LIRA-Ramadan™	A1	LIRA_SC	30	arm, events	35 / 172		R0025756:Supplement Table S2
LIRA-Ramadan™	A2	OTHER_ACTIVE_sulfonylurea	30	arm, events	1 / 171		R0025756:Supplement Table S2
NCT02200991	A1	LIXI_SC	4.43	arm, events	4 / 69		R0024589:Table 3
NCT02200991	A2	SITAGLIPTIN	4.43	arm, events	0 / 67		R0024589:Table 3
NCT00097500	A1	EXEN_SC	64	arm, events	4 / 36	nonserious_only	registry:adverse_events
NCT00097500	A2	INS_GLARGINE	64	arm, events	0 / 33	nonserious_only	registry:adverse_events
ACHIEVE-5	A1	PLACEBO	42	arm, events	0 / 141	nonserious_only	registry:adverse_events
ACHIEVE-5	A2+A3+A4	ORFO_PO	42	arm, events	60 / 405	nonserious_only;arms_combined	registry:adverse_events
NCT00894322	A1	EXENER_SC	12	arm, events	1 / 23	nonserious_only	registry:adverse_events
NCT00894322	A2	PLACEBO	12	arm, events	1 / 12	nonserious_only	registry:adverse_events
AWARD-CHN1	A1+A2	DULA_SC	26	arm, events	23 / 492	arms_combined	R0014229:Table 2
AWARD-CHN1	A3	GLIMEPIRIDE	26	arm, events	1 / 245		R0014229:Table 2
NCT00359762	A1	EXEN_SC	234.81	arm, events	44 / 515	nonserious_only	registry:adverse_events
NCT00359762	A2	GLIMEPIRIDE	234.81	arm, events	12 / 514	nonserious_only	registry:adverse_events
LIRA-SWITCH™	A1	LIRA_SC	27	arm, events	15 / 203		R0025720:Table 1
LIRA-SWITCH™	A2	SITAGLIPTIN	27	arm, events	10 / 204		R0025720:Table 1
AWARD-2	A1+A2	DULA_SC	78	arm, events	28 / 545	nonserious_only;arms_combined	registry:adverse_events
AWARD-2	A3	INS_GLARGINE	78	arm, events	3 / 265	nonserious_only	registry:adverse_events
DURATION-NEO-2	A1	EXENER_SC	28	arm, events	6 / 182		R0010641:Table 3
DURATION-NEO-2	A2	SITAGLIPTIN	28	arm, events	0 / 122		R0010641:Table 3
DURATION-NEO-2	A3	PLACEBO	28	arm, events	0 / 61		R0010641:Table 3
NCT05514535	A1	SEMA_SC	45	arm, events	28 / 288		R0015842:Table 2
NCT05514535	A2	INS_GLARGINE	45	arm, events	1 / 285		R0015842:Table 2
AWARD-6	A1	DULA_SC	30	arm, events	21 / 299	nonserious_only	registry:adverse_events
AWARD-6	A2	LIRA_SC	30	arm, events	25 / 300	nonserious_only	registry:adverse_events
GetGoal-M-Asia	A1	PLACEBO	24	arm, events	2 / 195	nonserious_only	registry:adverse_events
GetGoal-M-Asia	A2	LIXI_SC	24	arm, events	15 / 196	nonserious_only	registry:adverse_events
NCT03985293	A1	PLACEBO	20	arm, events	0 / 66		R0006095:Table 3
NCT03985293	A2+A3+A4+A5+A6	DANU_PO	20	arm, events	35 / 346	arms_combined	R0006095:Table 3
NCT00701935	A1	EXEN_SC	26.07	arm, events	7 / 43	nonserious_only	registry:adverse_events
NCT00701935	A2	PLACEBO	26.07	arm, events	3 / 37	nonserious_only	registry:adverse_events
NCT01191268	A1+A2	DULA_SC	56	arm, events	66 / 588	nonserious_only;arms_combined	registry:adverse_events
NCT01191268	A3	INS_GLARGINE	56	arm, events	5 / 296	nonserious_only	registry:adverse_events
LixiLan-O	A1	IGLARLIXI_SC	30.29	arm, events	15 / 469		R0015993:Table 1
LixiLan-O	A2	INS_GLARGINE	30.29	arm, events	7 / 467		R0015993:Table 1
LixiLan-O	A3	LIXI_SC	30.29	arm, events	15 / 234		R0015993:Table 1
GETGOAL-P	A1	PLACEBO	132	arm, events	8 / 161	nonserious_only	registry:adverse_events
GETGOAL-P	A2	LIXI_SC	132	arm, events	26 / 323	nonserious_only	registry:adverse_events
SUSTAIN™ 4	A1+A2	SEMA_SC	35	arm, events	61 / 722	nonserious_only;printed_denominator;arms_combined	registry:adverse_events
SUSTAIN™ 4	A3	INS_GLARGINE	35	arm, events	10 / 360	nonserious_only;printed_denominator	registry:adverse_events
NCT00375492	A1	EXEN_SC	24	arm, events	21 / 96	nonserious_only	registry:adverse_events
NCT00375492	A2	PLACEBO	24	arm, events	9 / 98	nonserious_only	registry:adverse_events
NCT04504396	A1	VISEPE_SC	24	arm, events	15 / 310		R0009432:Table 3
NCT04504396	A2	PLACEBO	24	arm, events	1 / 310		R0009432:Table 3
SURPASS-4	A1+A2+A3	TIRZ_SC	108	arm, events	72 / 997	arms_combined	R0007531:Supplement Table S2
SURPASS-4	A4	INS_GLARGINE	108	arm, events	16 / 1,005		R0007531:Supplement Table S2
NCT00877890	A1	EXENER_SC	24	arm, events	6 / 129	nonserious_only	registry:adverse_events
NCT00877890	A2	EXEN_SC	24	arm, events	11 / 125	nonserious_only	registry:adverse_events
SUSTAIN	A1+A2	SEMA_SC	35	arm, events	33 / 578	arms_combined	R0014802:Table 3
SUSTAIN	A3	SITAGLIPTIN	35	arm, events	3 / 290		R0014802:Table 3
NCT00360334	A1	EXEN_SC	26	arm, events	25 / 118	nonserious_only	registry:adverse_events
NCT00360334	A2	INS_GLARGINE	26	arm, events	6 / 117	nonserious_only	registry:adverse_events
DUAL™ V	A1	IDEGLIRA_SC	27	arm, events	14 / 278	nonserious_only	registry:adverse_events
DUAL™ V	A2	INS_GLARGINE	27	arm, events	5 / 279	nonserious_only	registry:adverse_events
NCT04552470	A1	PLACEBO	12	arm, events	0 / 9		R0004540:Table 2
NCT04552470	A2+A3+A4	DANU_PO	12	arm, events	16 / 28	arms_combined	R0004540:Table 2
NCT01003184	A1	EXENER_SC	26	arm, events	16 / 111		R0027663:Table 2
NCT01003184	A2	INS_DETEMIR	26	arm, events	9 / 111		R0027663:Table 2
SOLID-DKD	A1+A2	HRS7535_PO	18	arm, events	31 / 187	arms_combined	R0004355:Table 2
SOLID-DKD	A3	PLACEBO	18	arm, events	3 / 94		R0004355:Table 2
AWARD-CHN2	A1+A2	DULA_SC	52	arm, events	22 / 515	arms_combined	R0023722:Table 2
AWARD-CHN2	A3	INS_GLARGINE	52	arm, events	2 / 259		R0023722:Table 2
NCT00917267	A1	EXENER_SC	36	arm, events	27 / 340	nonserious_only;printed_denominator	registry:adverse_events
NCT00917267	A2	EXEN_SC	36	arm, events	39 / 338	nonserious_only;printed_denominator	registry:adverse_events
GETGOAL-X	A1	LIXI_SC	116	arm, events	41 / 320	nonserious_only	registry:adverse_events
GETGOAL-X	A2	EXEN_SC	116	arm, events	49 / 319	nonserious_only	registry:adverse_events
NCT00299871	A1	PLACEBO	13.43	arm, events	1 / 109		R0021613:Table 3
NCT00299871	A2+A3+A4+A5+A6+A7+A8+A9	LIXI_SC	13.43	arm, events	32 / 433	arms_combined	R0021613:Table 3
NCT02212067	A1	SEMA_SC	17	arm, events	6 / 37		R0021892:Results
NCT02212067	A2	PLACEBO	17	arm, events	2 / 38		R0021892:Results
SUSTAIN™	A1+A2	SEMA_SC	62	arm, events	27 / 480	arms_combined	R0025024:Table 2
SUSTAIN™	A3	OTHER_ACTIVE_additional_OAD	62	arm, events	2 / 121		R0025024:Table 2
LEAD-2	A1+A2+A3	LIRA_SC	104.28	arm, events	61 / 725	nonserious_only;arms_combined	registry:adverse_events
LEAD-2	A4	GLIMEPIRIDE	104.28	arm, events	1 / 244	nonserious_only	registry:adverse_events
LEAD-2	A5	PLACEBO	104.28	arm, events	0 / 122	nonserious_only	registry:adverse_events
NCT01620489	A1	LIRA_SC	27	arm, events	17 / 140	nonserious_only	registry:adverse_events
NCT01620489	A2	PLACEBO	27	arm, events	3 / 139	nonserious_only	registry:adverse_events
NCT05486065	A1+A2+A3	SEMA_SC	49	arm, events	41 / 185	nonserious_only;arms_combined	registry:adverse_events
NCT05486065	A4	PLACEBO	49	arm, events	4 / 60	nonserious_only	registry:adverse_events
GETGOAL-F1	A1	PLACEBO	112	arm, events	1 / 160	nonserious_only;printed_denominator	registry:adverse_events
GETGOAL-F1	A2+A3	LIXI_SC	112	arm, events	50 / 322	nonserious_only;arms_combined	registry:adverse_events
SURPASS-3	A1+A2+A3	TIRZ_SC	56	arm, events	91 / 1,079	arms_combined	R0015264:Table 2
SURPASS-3	A4	INS_DEGLUDEC	56	arm, events	4 / 365		R0007531:Supplement Table S2
NCT00460941	A1	PLACEBO	8	arm, events	0 / 32	printed_denominator	R0021258:Table 2
NCT00460941	A2+A3+A4	TASP_SC	8	arm, events	17 / 97	printed_denominator;arms_combined	R0021258:Table 2
SURPASS-5	A1+A2+A3	TIRZ_SC	44	arm, events	32 / 355	arms_combined	R0007531:Supplement Table S2
SURPASS-5	A4	PLACEBO	44	arm, events	3 / 120		R0007531:Supplement Table S2
NCT03322631	A1	PLACEBO	12	arm, events	0 / 9		R0021917:Table 2
NCT03322631	A2+A3+A4	TIRZ_SC	12	arm, events	4 / 39	arms_combined	R0021917:Table 2
NCT00744926	A1	PLACEBO	24	arm, events	0 / 123	printed_denominator	R0025346:Table 1
NCT00744926	A2+A3	TASP_SC	24	arm, events	43 / 245	printed_denominator;arms_combined	R0025346:Table 1
NCT00603239	A1	EXEN_SC	26	arm, events	9 / 111	nonserious_only	registry:adverse_events
NCT00603239	A2	PLACEBO	26	arm, events	0 / 54	nonserious_only	registry:adverse_events
PIONEER 1	A1+A2+A3	SEMA_PO	31	arm, events	25 / 525	nonserious_only;arms_combined	registry:adverse_events
PIONEER 1	A4	PLACEBO	31	arm, events	4 / 178	nonserious_only	registry:adverse_events
NCT00641056	A1	EXENER_SC	26	arm, events	9 / 233	count_from_percent	R0024240:Table 4
NCT00641056	A2	INS_GLARGINE	26	arm, events	2 / 234	count_from_percent	R0024240:Table 4
ELEGANT	A1	LIRA_SC	26	arm, events	6 / 26		R0025175:Table 3
ELEGANT	A2	STANDARD_CARE	26	arm, events	1 / 24		R0025175:Table 3
NCT01126580	A1+A2	DULA_SC	52	arm, events	46 / 539	nonserious_only;arms_combined	registry:adverse_events
NCT01126580	A3	METFORMIN	52	arm, events	14 / 268	nonserious_only	registry:adverse_events
NCT01272232	A1+A2	LIRA_SC	68	arm, events	87 / 634	nonserious_only;arms_combined	registry:adverse_events
NCT01272232	A3	PLACEBO	68	arm, events	12 / 212	nonserious_only	registry:adverse_events
NCT00943917	A1+A2	EXENIMP_IMPLANT	12	arm, events	15 / 102	nonserious_only;arms_combined	registry:adverse_events
NCT00943917	A3	EXEN_SC	12	arm, events	4 / 53	nonserious_only	registry:adverse_events
SUSTAIN 8	A1	SEMA_SC	57	arm, events	50 / 394	nonserious_only	registry:adverse_events
SUSTAIN 8	A2	CANAGLIFLOZIN	57	arm, events	9 / 394	nonserious_only	registry:adverse_events
SUSTAIN™ 5	A1+A2	SEMA_SC	35	arm, events	23 / 264	arms_combined	R0012671:Table 2
SUSTAIN™ 5	A3	PLACEBO	35	arm, events	4 / 133		R0012671:Table 2
NCT00382239	A1	PLACEBO	12	arm, events	0 / 40		R0027621:Table 3
NCT00382239	A2+A3+A4	EXEN_SC	12	arm, events	10 / 113	arms_combined	R0027621:Table 3
SUSTAIN™ 6	A1+A2	SEMA_SC	109	arm, events	209 / 1,648	nonserious_only;arms_combined	registry:adverse_events
SUSTAIN™ 6	A3+A4	PLACEBO	109	arm, events	75 / 1,649	nonserious_only;arms_combined	registry:adverse_events
SURPASS-SWITCH	A1	TIRZ_SC	44	arm, events	9 / 139	nonserious_only	registry:adverse_events
SURPASS-SWITCH	A2	DULA_SC	44	arm, events	14 / 143	nonserious_only	registry:adverse_events
AGAC2	A1	PLACEBO	0.43	arm, events	0 / 21		R0020827:Supplement Table 2
AGAC2	A2	EXEN_SC	0.43	arm, events	4 / 30		R0020827:Supplement Table 2
ACHIEVE-1	A1	PLACEBO	42	arm, events	2 / 138	nonserious_only	registry:adverse_events
ACHIEVE-1	A2+A3+A4	ORFO_PO	42	arm, events	36 / 421	nonserious_only;arms_combined	registry:adverse_events
NCT01632163	A1	LIXI_SC	24	arm, events	25 / 224		R0014725:Table 3
NCT01632163	A2	PLACEBO	24	arm, events	2 / 224		R0014725:Table 3
NCT00676338	A1	EXENER_SC	26	arm, events	12 / 248		R0027761:Results
NCT00676338	A2	METFORMIN	26	arm, events	8 / 246		R0027761:Results
NCT00676338	A3	PIOGLITAZONE	26	arm, events	5 / 163		R0027761:Results
NCT00676338	A4	SITAGLIPTIN	26	arm, events	3 / 163		R0027761:Results
NCT05086445	A1	PLACEBO	14	arm, events	1 / 11		R0003844:Table 2
NCT05086445	A2+A3+A4	ORFO_PO	14	arm, events	6 / 49	arms_combined	R0003844:Table 2
NCT00423501	A1	PLACEBO	12	arm, events	2 / 49	printed_denominator	R0022337:Table 2
NCT00423501	A2+A3+A4+A5+A6	TASP_SC	12	arm, events	33 / 248	printed_denominator;arms_combined	R0022337:Table 2
LIXILAN JP-O1	A1	IGLARLIXI_SC	52.43	arm, events	10 / 161		R0015751:Table 3
LIXILAN JP-O1	A2	LIXI_SC	52.43	arm, events	8 / 160		R0015751:Table 3
GETGOAL-L	A1	PLACEBO	125	arm, events	2 / 167	nonserious_only	registry:adverse_events
GETGOAL-L	A2	LIXI_SC	125	arm, events	32 / 329	nonserious_only	registry:adverse_events
PIONEER 5	A1	SEMA_PO	31	arm, events	19 / 163	nonserious_only	registry:adverse_events
PIONEER 5	A2	PLACEBO	31	arm, events	2 / 161	nonserious_only	registry:adverse_events
DUAL™ II Japan	A1	IDEGLIRA_SC	27	arm, events	9 / 105		R0015589:Table 2
DUAL™ II Japan	A2	INS_DEGLUDEC	27	arm, events	2 / 105		R0015589:Table 2
NCT03550378	A1	COTA_SC	8.43	arm, events	6 / 21		R0019218:Table 2
NCT03550378	A2	PLACEBO	8.43	arm, events	1 / 20		R0019218:Table 2
AMPLITUDE-M	A1+A2+A3	EFPE_SC	56	arm, events	20 / 304	arms_combined	R0007136:Table 2
AMPLITUDE-M	A4	PLACEBO	56	arm, events	0 / 102		R0007136:Table 2
NCT02288273	A1	EXENER_SC	14	arm, events	2 / 61	nonserious_only	registry:adverse_events
NCT02288273	A2	PLACEBO	14	arm, events	0 / 56	nonserious_only	registry:adverse_events
LEAD-5	A1	LIRA_SC	27	arm, events	15 / 232		R0027336:Supplement Table 2
LEAD-5	A2	PLACEBO	27	arm, events	4 / 115		R0027336:Supplement Table 2
LEAD-5	A3	INS_GLARGINE	27	arm, events	1 / 234		R0027336:Supplement Table 2
Lixilan-L-CN	A1	IGLARLIXI_SC	30.43	arm, events	1 / 212		R0014540:Table 3
Lixilan-L-CN	A2	INS_GLARGINE	30.43	arm, events	2 / 214		R0014540:Table 3
NCT04998032	A1	EFSUBA_SC	24	arm, events	17 / 171		R0006975:Table 3
NCT04998032	A2	PLACEBO	24	arm, events	3 / 173		R0006975:Table 3
AWARD-1	A1+A2	DULA_SC	56	arm, events	65 / 559	nonserious_only;arms_combined	registry:adverse_events
AWARD-1	A3	EXEN_SC	56	arm, events	34 / 278	nonserious_only	registry:adverse_events
GETGOAL-M	A1+A2	LIXI_SC	76.43	arm, events	75 / 510	nonserious_only;arms_combined	registry:adverse_events
GETGOAL-M	A3	PLACEBO	76.43	arm, events	9 / 170	nonserious_only;printed_denominator	registry:adverse_events
NCT01425580	A1	LIRA_SC	18	arm, events	1 / 33	nonserious_only	R0025885:Results
NCT01425580	A2	GLIMEPIRIDE	18	arm, events	1 / 29	nonserious_only	R0025885:Results
NCT03311724	A1	PLACEBO	16	arm, events	1 / 26		R0010282:Table 2
NCT03311724	A2+A3+A4	TIRZ_SC	16	arm, events	15 / 85	arms_combined	R0010282:Table 2
NCT05048719	A1	PLACEBO	28	arm, events	1 / 55	nonserious_only	registry:adverse_events
NCT05048719	A2+A3+A4+A5+A6+A7+A8	ORFO_PO	28	arm, events	62 / 278	nonserious_only;arms_combined	registry:adverse_events
NCT05048719	A9	DULA_SC	28	arm, events	4 / 50	nonserious_only	registry:adverse_events
PIONEER 3	A1+A2+A3	SEMA_PO	83	arm, events	82 / 1,397	nonserious_only;arms_combined	registry:adverse_events
PIONEER 3	A4	SITAGLIPTIN	83	arm, events	19 / 467	nonserious_only	registry:adverse_events
NCT04466904	A1+A2+A3	MAZD_SC	20	arm, events	1 / 24	arms_combined	R0009340:Table 2
NCT04466904	A4	DULA_SC	20	arm, events	1 / 6	printed_denominator	R0009340:Table 2
NCT04466904	A5	PLACEBO	20	arm, events	0 / 12	printed_denominator	R0009340:Table 2
GETGOAL-MONO	A1	PLACEBO	12.43	arm, events	0 / 122	printed_denominator	R0022843:Table 2
GETGOAL-MONO	A2+A3	LIXI_SC	12.43	arm, events	17 / 239	arms_combined	R0022843:Table 2
NCT00700817	A1+A2	LIRA_SC	52	arm, events	41 / 446	arms_combined	R0024199:Table 2
NCT00700817	A3	SITAGLIPTIN	52	arm, events	11 / 219		R0024199:Table 2
PIONEER 8	A1+A2+A3	SEMA_PO	57	arm, events	42 / 547	nonserious_only;arms_combined	registry:adverse_events
PIONEER 8	A4	PLACEBO	57	arm, events	7 / 184	nonserious_only	registry:adverse_events
NCT06256523	A1	BOFANG_SC	29	arm, events	0 / 27	printed_denominator	R0002476:Table 2
NCT06256523	A2	PLACEBO	29	arm, events	0 / 9	printed_denominator	R0002476:Table 2
S002858	A1	LIXI_SC	24	arm, events	3 / 51		R0001573:Supplement Table S1
S002858	A2	PLACEBO	24	arm, events	2 / 50		R0001573:Supplement Table S1
S002928	A1	PLACEBO	24	arm, events	0 / 41		R0007034:Table 4
S002928	A2+A3	PEGLOX_SC	24	arm, events	3 / 82	arms_combined	R0007034:Table 4
S002946	A1	SEMA_SC	26	arm, events	2 / 16		R0006360:Supplement Table S2
S002946	A2	DULA_SC	26	arm, events	0 / 16		R0006360:Supplement Table S2
S002947	A1+A2+A3	ECNO_SC	25	arm, events	3 / 109	arms_combined	R0006482:Table 3
S002947	A4	PLACEBO	25	arm, events	0 / 36		R0006482:Table 3
S002951	A1	PEGLOX_SC	16	arm, events	6 / 104		R0007588:Table 3
S002951	A2	METFORMIN	16	arm, events	1 / 52		R0007588:Table 3
NCT05654831	A1+A2+A3+A4	ECC500_PO	4.86	arm, events	3 / 39	arms_combined	R0007796:Table 2
NCT05654831	A5	PLACEBO	4.86	arm, events	0 / 13		R0007796:Table 2
S003009	A1	PEGLOX_SC	24	arm, events	1 / 44		R0011381:Table 4
S003009	A2	DAPAGLIFLOZIN	24	arm, events	0 / 44		R0011381:Table 4
S003023	A1	LIRA_SC	0.43	arm, events	2 / 32	printed_denominator	R0017408:Results
S003023	A2	STANDARD_CARE	0.43	arm, events	0 / 28	printed_denominator	R0017408:Table 5
S003047	A1+A2	LIXI_SC	6.57	arm, events	11 / 80	printed_denominator;arms_combined	R0016337:Table 3
S003047	A3	PLACEBO	6.57	arm, events	0 / 40	printed_denominator	R0016337:Table 3
S003058	A1	LIXI_SC	12	arm, events	1 / 23		R0024376:Results
S003058	A2	VILDAGLIPTIN	12	arm, events	0 / 25		R0024376:Results
S003079	A1	EXEN_SC	5	arm, events	0 / 18		R0025923:Results
S003079	A2	STANDARD_CARE	5	arm, events	0 / 18		R0025923:Results

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab